Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J. Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Michelle Lai, Céline Fournier-Poizat, Grace Lai-Hung Wong, Mirko Zoncape, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Llop, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Mandy Sau-Wai Chan, Clemence M Canivet, Manuel Romero-Gomez, Vincent Wai-Sun Wong, Seung Up Kim, Terry Cheuk-Fung Yip
Clin Mol Hepatol 2026;32(1):289-304. Published online November 11, 2025
Background/Aims Current guidelines recommend a 2-step approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE). However, some patients may exhibit discordant results. This study evaluates the histological severity and outcomes in patients with discordant FIB-4 and LSM results.
Methods This secondary analysis of the VCTE-Prognosis study included 12,950 patients evaluated for MASLD at 16 tertiary centers, of whom 2,915 underwent liver biopsy. Patients were categorized into four groups based on established FIB-4 (1.3) and LSM (8 kPa) cutoffs.
Result s: F3–F4 fibrosis was observed in 6.4%, 13.7%, 30.6%, and 62.4% in low-FIB-4-low-LSM (n=6,403), high-FIB-4-low-LSM (n=3,017), low-FIB-4-high-LSM (n=1,363), and high-FIB-4-high-LSM (n=2,167) groups, respectively. During a median follow-up of 47.4 months, 248 patients experienced hepatic decompensation, hepatocellular carcinoma, liver transplantation, or liver-related death. The incidence rates of liver-related events (LREs) were 0.67, 1.19, 2.58, and 21.30 per 1,000 person-years, respectively. Compared to low-FIB-4-low-LSM patients, those with low-FIB-4-high-LSM (adjusted subdistribution hazard ratio [aSHR] 4.12) and high-FIB-4-high-LSM (aSHR 21.38) had a significantly higher risk of LREs, while high-FIB-4-low-LSM patients did not. Similar findings were observed when hepatic decompensation and hepatocellular carcinoma were analyzed separately.
Conclusions Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LREs remains low.
Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes Na Tian, Tie Xiao, Tianyi Xia, Hai‐Yang Yuan, Michael D. Shapiro, Gregory Y. H. Lip, Cheng‐Han Fanren, Li‐You Lian, Chen‐Xiao Huang, Yi‐Xuan Wei, Giovanni Targher, Christopher D. Byrne, Cheng‐Lv Hong, Shenghong Ju, Ming‐Hua Zheng Alimentary Pharmacology & Therapeutics.2026; 63(1): 70. CrossRef
Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply Xiao‐Dong Zhou, Yusuf Yilmaz, Ming‐Hua Zheng Alimentary Pharmacology & Therapeutics.2026; 63(1): 155. CrossRef
Statins in MASLD: Challenges and Future Xiao-Dong Zhou, Mark D. Muthiah, Ming-Hua Zheng JHEP Reports.2025; : 101372. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
The association of advanced lung cancer inflammation index with non-alcoholic fatty liver disease in NHANES 2017–2020 Lin Cheng, Shumeng Li, Hui Li, Jiafeng You, Mingwei Yu, Guowang Yang Frontiers in Medicine.2025;[Epub] CrossRef
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD Xiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen, Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.
Citations
Citations to this article as recorded by
Radish Green Extract Attenuates Western Diet-Induced Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice Hye-Bin Lee, Yu Ra Lee, Eunjung Lee, Seong Un Jeong, Jae-Hyun Yoon, Miri Park, Yoonsook Kim, Ho-Young Park Journal of Agricultural and Food Chemistry.2026; 74(1): 874. CrossRef
Multi-omics reveal the key role of gut microbiota metabolism in adenine-induced chronic kidney disease Yijing Xin, Hui Ma, Xiang Li, Ruiyang Sun, Luo Fang, Libin Pan Toxicology and Applied Pharmacology.2026; 509: 117754. CrossRef
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Journal of Clinical Medicine.2025; 14(11): 3911. CrossRef
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease? Jiang Bai, Lijuan Zhang, Letian He, Yun Zhou Frontiers in Nutrition.2025;[Epub] CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Quyu Huazhuo Decoction alleviates non-Alcoholic steatohepatitis via remodeling the gut microbiota and regulating bile acid and short-chain fatty acid metabolism Lu Lu, Chengting Wu, Juhong Jia, Yuanqin Du, Yujiao Peng, Hongna Huang, Jingjing Huang, Yaobin Nong Journal of Chromatography B.2025; 1267: 124784. CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano Exploration of Medicine.2025;[Epub] CrossRef
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications Wenhua Bai, Zheng Zhu Frontiers in Endocrinology.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis are Associated with Advanced Cardiovascular-Kidney-Metabolic Syndrome in Chinese and US Populations Shidi Hu, Dongmei Wang, Qingtao Yu, Zhi Chen, Weiguo Lu, Yuan Meng, Xuetao Peng, Lan Liu, Heng Wan, Jie Shen Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4699. CrossRef
“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.
Citations
Citations to this article as recorded by
Astragaloside IV alleviates metabolic associated fatty liver disease by regulating ferroptosis via the SLC7A11/GPX4 pathway Sitong CHEN, Hanying XU, Zipei ZHANG, Xiaonan LI, Xiaolei TANG, Dashi YING Chinese Journal of Analytical Chemistry.2026; 54(2): 100625. CrossRef
Associations between per- and polyfluoroalkyl substances and metabolic dysfunction-associated steatotic liver disease in adolescents and young adults: modifying roles of age, lifestyle factors, and PNPLA3 genotype Shiwen Li, Jiawen Carmen Chen, Elizabeth Costello, Douglas I. Walker, Jesse A. Goodrich, Lily Dara, Lucy Golden-Mason, Ana C. Maretti-Mira, Scott M. Bartell, Veronica M. Vieira, Tanya L. Alderete, Michael I. Goran, Zhanghua Chen, Frank D. Gilliland, Britt Environmental Research.2026; 288: 123320. CrossRef
Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis Jiamei Song, Dan Liu, Jitong Li, Haoru Cong, Ruixue Deng, Yihan Lu, Jiayi Sun, Jingzhou Zhang Journal of Medical Internet Research.2026; 28: e78310. CrossRef
A multicenter trial to test pitavastatin calcium in youth with combined dyslipidemia of obesity: Design, implementation, challenges, and responses Sarah D. de Ferranti, Jessica E. Teng, Silva A. Arslanian, Andrew M. Atz, Julie A. Brothers, Mark J. Cartoski, D’Andrea R. Freemon, Sheela N. Magge, William T. Mahle, Michele Mietus-Snyder, Amy Peterson, Geetha Raghuveer, Mark W. Russell, Amy S. Shah, Cra American Heart Journal.2026; 294: 107327. CrossRef
A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma J. M. John Britto, T Beula Bell Irish Journal of Medical Science (1971 -).2026;[Epub] CrossRef
Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases Huiting Che, Yidan Gao, Yonghu Xu, Hui Xu, Roland Eils, Mei Tian Signal Transduction and Targeted Therapy.2026;[Epub] CrossRef
Prevalence and importance of periodontal disease in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Veracruz L. Roesch-Ramos, D.N. Guzmán-Uzcanga, S. Nolasco-Polito, S. Pérez-Pérez, F. Moreno-Marín, R.M. Francisco, H.R. Ordaz-Álvarez, F.B. Roesch-Dietlen, J.M. Remes-Troche, A.D. Cano-Contreras Revista de Gastroenterología de México (English Edition).2026;[Epub] CrossRef
Subtype-specific associations of steatotic liver disease with gastric and esophageal cancers: a nationwide cohort study Yeo Wool Kang, Minkook Son, Jong Yoon Lee, Sang Yi Moon, Myeongseok Koh Gastric Cancer.2026;[Epub] CrossRef
Gpx4 Deletion‐Mediated Macrophage Ferroptosis Alleviates Obesity‐Associated Insulin Resistance Suhua Wu, Juan Peng, Xiaodong Wang, Hong Gao, Huangrui Fang, Shiyi Hu, Qiufen Wei, Yuanye Dang, Haixia Tu, Mingyan Zhu, Jianye Peng, Yumiao Liu, Gaofeng Zeng, Xiaoyan Dai The FASEB Journal.2026;[Epub] CrossRef
Combination of GLP-1 receptor agonist and Akkermansia muciniphila Akk11 reduces adiposity and ameliorates MASLD in T2D mice Kaige Gao, Zaifei Yin, Chi Zhang, Zixuan Dong, Runqi Wang, Qian Chen, Xiangpeng Liu, Caifeng Jiang, Yalin Wang, Bin Guo, Zhengyu Zhou, Zhihao Jia, Hong Sun, Yu Feng Cell & Bioscience.2026;[Epub] CrossRef
Choline Deficiency Drives the Inflammation–Fibrosis Cascade: A Spatiotemporal Atlas of Hepatic Injury from Weeks 6 to 10 Shang Li, Guoqiang Zhang, Xiaohong Li, Xu Zhao, Axi Shi, Qingmin Dong, Changpeng Chai, Xiaojing Song, Yuhui Wei, Xun Li Antioxidants.2026; 15(1): 110. CrossRef
Using Large Language Models to Predict Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Proof-of-Concept Analysis Basile Njei, Nelvis Njei, Sarpong Boateng, Omar Al Ta'ani, Yazan Al-Ajlouni Cureus.2026;[Epub] CrossRef
Network Pharmacology-Based Investigation of the Mechanism of Liupao Tea Polyphenol Extract in Preventing MAFLD via the Hepatic EGFR–AKT Pathway Jirui Wei, Xiaozheng He, Tingting Shi, Xiayu Jin, Jun Huang, Qingyao Du, Junda Huang, Tao Li, Xunjie Xie, Yuxin Huang, Chengtao Nie, Yiqi Fan, Xixiao Yang, Luyao Song, Waijiao Tang Journal of Agricultural and Food Chemistry.2026;[Epub] CrossRef
Procyanidin B2 and an autochthonous apple pulp extract modulate oxidative stress and PPARγ expression on an in vitro model of lipid steatosis in HepG2 cells Adrián Millán-Laleona, Marta Lopez-Yus, Silvia Lorente-Cebrián, Jose M. Arbones-Mainar, Carlota Gómez-Rincón, Víctor López Journal of Physiology and Biochemistry.2026;[Epub] CrossRef
The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease Ioannis Tsomidis, Angeliki Tsakou, Argyro Voumvouraki, Elias Kouroumalis Biomedicines.2026; 14(1): 151. CrossRef
Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study Yaxuan He, Yu Cao, Zekai Chen, Rong Xiang, Fang Wang Scientific Reports.2026;[Epub] CrossRef
Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities Zoubiri Houda, Saiah Wassila, Otmane Amel, Saidi Hamza, Makrelouf Mohamed, Aitabderrhmane Samir, Haddam Ali El Mahdi, Koceir Elhadj-Ahmed International Journal of Molecular Sciences.2026; 27(3): 1218. CrossRef
Mediating role of metabolic dysfunction-associated fatty liver disease in the association between individual-level noise exposure and liver enzymes in Chinese automotive manufacturing workers Sijia Ou, Jiaheng Yu, Zhaoqian Chen, Yanmei Ruan, Xing Rong, Zejin Ou, Yuxia Zhang, Haijuan Huang, Jiaxin Cui, Zhi Wang International Archives of Occupational and Environmental Health.2026;[Epub] CrossRef
Efficacy of selected dietary supplements and pharmacological agents on metabolic and oxidative stress outcomes in metabolic dysfunction–associated fatty liver disease (MAFLD): a Bayesian network meta-analysis Yunyi Yang, Xiaoli He, Jiayuan Cai, Xiaoxiao Qu, Shufa Tan, Jiawen You, Yanming He, Zheng Yao, Hongjie Yang Frontiers in Pharmacology.2026;[Epub] CrossRef
Efficacy and safety of lower-carbohydrate dietary patterns for metabolic associated fatty liver disease: evidence from randomized controlled trials with grade analysis Yunhang Chu, Ming Yang, Qi Meng, Delong Cong, Lingyu Xu, Peng Dai, Ziqiang Chen, Sulan Chen, Rui Zhang, Yan Leng Nutrition & Metabolism.2026;[Epub] CrossRef
Risk Assessment for Carotid Atherosclerosis in Asymptomatic Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Hana Park, Ji Young Lee, Sungwon Park, Hyo Jeong Lee, Suh Eun Bae, Jaeil Kim, Hye-Sook Chang, Jaewon Choe, Hye Won Park, Ju Hyun Shim Gut and Liver.2026; 20(1): 125. CrossRef
Research on the Therapeutic Effect and Mechanism of Stir-Roasted Deer Velvet Antler with Ghee on Non-Alcoholic Fatty Liver Disease Xuan He, Yinghan Liu, Shuning Cui, Zhenming Yu, Zhongmei He, Ying Zong, Weijia Chen, Jianan Geng, Jia Zhou, Zhuo Li, Yan Zhao, Hongbo Teng Nutrients.2026; 18(3): 401. CrossRef
Hepatoprotective Ergostane and Lanostane Derivatives from Mushrooms for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease: A Review
K.Razak Deen, S. Rithick, M. Muthumari, D. Jayakumar, N. Amrith Sam, K. Balakrishna, Perumal Pandikumar, Savarimuthu Ignacimuthu International Journal of Medicinal Mushrooms.2026; 28(2): 1. CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
La phospholipase A2 associée aux lipoprotéines (Lp-PLA2) : biomarqueur pertinent et cible thérapeutique ? Dominique Bonnefont-Rousselot Annales Pharmaceutiques Françaises.2025; 83(1): 45. CrossRef
Comparing Three Ultrasound-Based Techniques for Diagnosing and Grading Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Pingping Wang, Danlei Song, JiaHao Han, Jing Zhang, Huihui Chen, Ruixia Gao, Huiming Shen, Jia Li Academic Radiology.2025; 32(4): 1949. CrossRef
The Effect of Curcumin on Glucolipid Metabolic Disorders: A Review Lifen Mo, Siyu Wan, Tekla Zékány-Nagy, Xiaoyi Luo, Xingfen Yang Food Reviews International.2025; 41(2): 543. CrossRef
Unveiling the nexus: pyroptosis and its crucial implications in liver diseases Zeyu Miao, Xiaorong Zhang, Yang Xu, Yan Liu, Qing Yang Molecular and Cellular Biochemistry.2025; 480(4): 2159. CrossRef
MASLD, MLA Pesarattu and Other Developments Anil C. Anand Journal of Clinical and Experimental Hepatology.2025; 15(1): 102465. CrossRef
Elevated concurrent carotid atherosclerosis rates in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) compared to non-alcoholic fatty liver disease (NAFLD): A cross-sectional observational study Nien-Ting Chung, Chiann-Yi Hsu, Nai-Chen Shih, Jia-Jyun Wu Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(1): 103767. CrossRef
Sex Hormone: A Potential Target at Treating Female Metabolic Dysfunction-Associated Steatotic Liver Disease? Huiyan Duan, Minmin Gong, Gang Yuan, Zhi Wang Journal of Clinical and Experimental Hepatology.2025; 15(2): 102459. CrossRef
Impact of Nonalcoholic Fatty Liver Disease on Weight Loss Outcomes After One Anastomosis Gastric Bypass Rahmatullah Athar, Masoumeh Shahsavan, Shahab Shahabi, Abdolreza Pazouki, Farah A. Husain, Mohammad Kermansaravi Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2025;[Epub] CrossRef
Trehalose Ameliorates Nonalcoholic Fatty Liver Disease by Regulating IRE1α–TFEB Signaling Pathway Shan Su, Xiaohong Liu, Min Zhu, Wen Liu, Jingyi Liu, Yujia Yuan, Fudong Fu, Zhiyong Rao, Jingping Liu, Yanrong Lu, Younan Chen Journal of Agricultural and Food Chemistry.2025; 73(1): 521. CrossRef
Deterioration of endothelial function as a risk factor for osteoporosis in patients with type 2 diabetes mellitus and MAFLD Alexander E. Berezin Acta Cardiologica.2025; 80(1): 99. CrossRef
Vitamin D supplementation alleviates high fat diet-induced metabolic associated fatty liver disease by inhibiting ferroptosis pathway Yufan Miao, Zhongyan Jiang, Hanlu Song, Yujing Zhang, Hao Chen, Wenyi Liu, Xiaonuo Wei, Longkang Li, Wenjie Li, Xing Li European Journal of Nutrition.2025;[Epub] CrossRef
Fermented rhubarb alleviates metabolic dysfunction-associated steatotic liver disease symptoms by modulating gut microbiota and activating the hepatic insulin signaling pathway Heng Yuan, Junyu Zhou, Ting Zhang, Xuangao Wu, Chen Li, Hee-Jong Yang, Do Yeon Jeong, Sunmin Park Food Bioscience.2025; 63: 105720. CrossRef
Quercetin alleviates metabolic-associated fatty liver disease by tuning hepatic lipid metabolism, oxidative stress and inflammation Ling Jiang, Rong Yi, Huan Chen, Shuwu Wu Animal Biotechnology.2025;[Epub] CrossRef
Valorizing Agro‐Food Waste for Nutraceutical Development: Sustainable Approaches for Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Related Co‐Morbidities Laura Comi, Claudia Giglione, Fationa Tolaj Klinaku, Federico Pialorsi, Valentina Tollemeto, Maria Zurlo, Antonio Seneci, Paolo Magni Food Frontiers.2025; 6(2): 670. CrossRef
Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease Yu-Hong Fan, Siyao Zhang, Ye Wang, Hongni Wang, Hongliang Li, Lan Bai Frontiers in Endocrinology.2025;[Epub] CrossRef
Altered kidney function in fatty liver disease: confronting the “MAFLD-renal syndrome” Suleiman Al Ashi, Ali A. Rizvi, Manfredi Rizzo Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
Correlation between hepatic steatosis severity diagnosed by ultrasound and metabolic indexes in elderly patients with MAFLD Zhitang Liang, Renhao Huang, Lingyun Zhang Frontiers in Medicine.2025;[Epub] CrossRef
Exposure to a choline-deficient diet during pregnancy and lactation alters the liver transcriptome profile in offspring of dams with fatty liver Joanna Mikołajczyk-Stecyna, Ewelina Zuk, Agata Chmurzynska, Malgorzata Blatkiewicz, Karol Jopek, Marcin Rucinski Clinical Nutrition ESPEN.2025; 66: 9. CrossRef
miR‐18a‐5p/PXR/SREBP2 Was Involved in MAFLD Associated With Methyl Tert‐Butyl Ether Among Petrol Station Workers Hanyun Wang, Mingxiao Guo, Fengtao Cui, Mengdi Li, Xianan Zhang, Wei Gao, Xingqiang Fang, Li Chen, Ye Xin, Yucheng Sun, Piye Niu, Junxiang Ma Liver International.2025;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease and risk of nephrolithiasis: a sizeable cross-sectional study Shengqi Zheng, Tianchi Hua, Guicao Yin, Wei Zhang, Xiaoxiang Wang, Lezhong Qi, Xiayong Jing, Qibing Fan, Xiaoping Yu, Yifan Li Frontiers in Endocrinology.2025;[Epub] CrossRef
Endogenous Ethanol Production in the Human Alimentary Tract: A Literature Review Renee Stamation Journal of Gastroenterology and Hepatology.2025; 40(4): 783. CrossRef
Serum Lactate Dehydrogenase Is a Novel Predictor for the Severity in the Patients With MAFLD: A Cross-Sectional Study in Hefei, China Liang Yu, Shiming Bao, Feng Zhu, Yanyan Xu, Fuqiang Zu, Yanwei Liu, Runbeng Jiang, Song Chen, Wei Chen Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 345. CrossRef
Research progress of cysteine transporter SLC7A11 in endocrine and metabolic diseases Jiaqi Chen, Mengzhu Yuan, Jianping Wang Molecular Biology Reports.2025;[Epub] CrossRef
Obesity and Adipose-Derived Extracellular Vesicles: Implications for Metabolic Regulation and Disease Michele Malaguarnera, Omar Cauli, Andrea Cabrera-Pastor Biomolecules.2025; 15(2): 231. CrossRef
Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis Kathryn J Potter, Jackie Phinney, Tasha Kulai, Vicki Munro Journal of the Canadian Association of Gastroenterology.2025; 8(2): 47. CrossRef
IFN-γ-mediated inhibition of JAK/STAT signaling via nano-scutellarin treatment is an efficient strategy for ameliorating liver fibrosis Ting Wang, Bangguo Liu, Juan Huang, Qixin Zhao, Hongping Shen, Tao Bi, Zengjin Liu, Yong Dai, Qin Sun Journal of Translational Medicine.2025;[Epub] CrossRef
Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo International Journal of Molecular Sciences.2025; 26(4): 1778. CrossRef
Psychosocial risks in metabolic dysfunction-associated steatotic liver disease Hanne Åström, Christine Takami Lageborn, Hannes Hagström Expert Review of Gastroenterology & Hepatology.2025; 19(3): 273. CrossRef
Racial Disparities in Mortality Rates among Patients with Hepatic Steatosis, Non-Alcoholic Fatty Liver Disease, and Non-Alcoholic Steatohepatitis: Insights from NHANES III Data Shahrzad Bazargan-Hejazi, Cameron Hines, Myra Usmani, Chris Argueta, Deyu Pan, Arleen F. Brown Journal of Racial and Ethnic Health Disparities.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in adults Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba Nature Reviews Disease Primers.2025;[Epub] CrossRef
A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies Izabela Berdowska, Małgorzata Matusiewicz, Izabela Fecka International Journal of Molecular Sciences.2025; 26(6): 2394. CrossRef
A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease Michelle Thuy Nguyen, Andrew Lian, Frederick Timothy Guilford, Vishwanath Venketaraman Biomedicines.2025; 13(3): 644. CrossRef
Red Meat Amino Acids for Beginners: A Narrative Review Benjamin Barr, Danielle E. Levitt, Lauren Gollahon Nutrients.2025; 17(6): 939. CrossRef
Clinical Insights into Non-Alcoholic Fatty Liver Disease and the Therapeutic Potential of Flavonoids: An Update Aleksandra Kozłowska Nutrients.2025; 17(6): 956. CrossRef
Estimated sdLDL-C as a biomarker of hepatic steatosis severity in MASLD: a retrospective study Shuo Jiang, Fan Zhang, Hui Yang, Xue Han, Jieru Mao, Guojun Zheng, Yan Fan BMC Gastroenterology.2025;[Epub] CrossRef
Fu brick tea supplementation ameliorates non-alcoholic fatty liver disease and associated endotoxemia via maintaining intestinal homeostasis and remodeling hepatic immune microenvironment Gaolong Zuo, Menghua Li, Xiaoli Guo, Ling Wang, Yanyan Yao, Jian-an Huang, Zhonghua Liu, Yong Lin Food Research International.2025; 209: 116207. CrossRef
Association of occupational physical activity and sedentary behaviour with the risk of hepatocellular carcinoma: a case-control study based on the Inpatient Clinico-Occupational Database of Rosai Hospital Group Shoko Nakazawa, Kota Fukai, Kei Sano, Yuko Furuya, Keika Hoshi, Noriko Kojimahara, Akihiro Toyota, Masaaki Korenaga, Masayuki Tatemichi BMJ Open.2025; 15(3): e092020. CrossRef
Impact of blood lead and manganese levels on metabolic dysfunction-associated steatotic liver disease prevalence: insights from NHANES (2017–2020) Wenying Guo, Ting Weng, Yufei Song BMC Gastroenterology.2025;[Epub] CrossRef
Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases Patrizia Burra, Calogero Cammà, Pietro Invernizzi, Fabio Marra, Maurizio Pompili Annals of Hepatology.2025; 30(1): 101900. CrossRef
Omega-3 Fatty Acids, Furan Fatty Acids, and Hydroxy Fatty Acid Esters: Dietary Bioactive Lipids with Potential Benefits for MAFLD and Liver Health Camil Merheb, Sabine Gerbal-Chaloin, François Casas, Mona Diab-Assaf, Martine Daujat-Chavanieu, Christine Feillet-Coudray Nutrients.2025; 17(6): 1031. CrossRef
Photon-counting CT–derived Quantification of Hepatic Fat Fraction: A Clinical Validation Study Tatjana Dell, Narine Mesropyan, Yannik Layer, Verena Tischler, Leonie Weinhold, Johannes Chang, Christian Jansen, Bernhard Schmidt, Markus Jürgens, Alexander Isaak, Patrick Kupczyk, Claus Christian Pieper, Carsten Meyer, Julian Luetkens, Daniel Kuetting Radiology.2025;[Epub] CrossRef
Unravelling the Role of PANoptosis in Liver Diseases: Mechanisms and Therapeutic Implications Wanyuan Xiong, Junfeng Li, Aiping Tian, Xiaorong Mao Liver International.2025;[Epub] CrossRef
Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020 Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu Frontiers in Physiology.2025;[Epub] CrossRef
Metrology for MRI: the field you’ve never heard of Matt G. Hall, Matt Cashmore, Hyo-Min Cho, Bernd Ittermann, Kathryn E. Keenan, Christoph Kolbitsch, Changwoo Lee, Chengwei Li, Asante Ntata, Katie Obee, Zhang Pu, Stephen E. Russek, Karl F. Stupic, Lukas Winter, Luca Zilberti, Michael Steckner Magnetic Resonance Materials in Physics, Biology and Medicine.2025; 38(3): 387. CrossRef
Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement Mengdi Zhang, Jinliang Ji, Yuanyuan Lei, Fujian Qin, Yitong Tao, Ning Li, Jinlei Bian, Zhiyu Li, Maode Lai, Zhixia Qiu Pharmacological Research.2025; 215: 107706. CrossRef
MASLD or MAFLD: fatty liver by any name will pose the same challenge Anil Chandra Anand, Dibyalochan Praharaj Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways Setareh Satari, Inês N. R. Mota, Ana Carolina Leão Silva, Haissa Oliveira Brito, Paula A. Oliveira, Rui Miguel Gil da Costa, Rui Medeiros International Journal of Molecular Sciences.2025; 26(9): 3952. CrossRef
Relationship of serum 25(OH)D3 and PTX3 with liver fat content in patients with non-alcoholic fatty liver disease: Diagnostic value for liver fibrosis Jian-Ji Dai, Yi Deng, Guo-Feng Wang, Kai-Qin Lin, Jian-Rong He, Xiao-Gang Hu World Chinese Journal of Digestology.2025; 33(3): 192. CrossRef
Role of regulatory T cells in inflammatory liver diseases Linjie Yang, Song Guo Zheng Autoimmunity Reviews.2025; 24(6): 103806. CrossRef
Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis Qihua Duan, Ruixiang Hu, Yan Chen, Henry Wade, Szczepan Kaluzny, Bingrui Zhang, Rongxue Wu, Guangnan Liu, Cunchuan Wang, Edward N. Harris, Qiaozhu Su Genes & Diseases.2025; 12(6): 101648. CrossRef
Association of serum iron status with MASLD and liver fibrosis Wenying Guo, Ting Weng, Yufei Song, Anna Di Sessa PLOS ONE.2025; 20(4): e0319057. CrossRef
Nephrological, Pulmonary, and Dermatological Complications in the Context of MAFLD/NAFLD: A Narrative Review Vlad Pădureanu, Dalia Dop, Lucrețiu Radu, Dumitru Rădulescu, Rodica Pădureanu, Denisa Floriana Vasilica Pîrșcoveanu, Daniel Cosmin Caragea Metabolites.2025; 15(4): 272. CrossRef
Rhizoma Atractylodis Macrocephalae reduces HFD-induced NAFLD in mice through activated AMPK mediated inhibition of fatty acid synthesis Ke Zheng, RuiShuo Zhang, Yijing Xin, Yuge Zhou, Jiacheng Lin, Weifan Huang, Fang Wang, Liu Yang, Xuehua Sun, Xiaoni Kong Liver Research.2025;[Epub] CrossRef
Increased Mechanical Index Improves Shear Wave Elastography: Pilot Study of Signal Enhancement Scott Schoen, Michael Wang, Sunethra Dayavansha, Kim Naja, Viksit Kumar, Rimon Tadross, Kathleen Pope, Lauren Ling, David Hunt, Mary K. Peters, Ann Iafrate, Nathaniel D. Mercaldo, Kurt Sandstrom, TaeYun Kim, Mike Washburn, Theodore T. Pierce, Anthony E. S Ultrasound in Medicine & Biology.2025; 51(7): 1070. CrossRef
A Systematic Review of the Beneficial Effects of Berry Extracts on Non-Alcoholic Fatty Liver Disease in Animal Models Alejandro García-Beltrán, Aida Lozano Melero, Rosario Martínez Martínez, Jesús María Porres Foulquie, María López Jurado Romero de la Cruz, Garyfallia Kapravelou Nutrition Reviews.2025; 83(5): 819. CrossRef
Linghe granules reduces hepatic lipid accumulation in Non-alcoholic fatty liver disease through regulating lipid metabolism and redox balance Yuting Hu, Ni'ao Li, Rumian Zhang, Jia Wang, Dongdong Fang, Qianmei Zhou, Hua Zhang, Hong Cai, Yiyu Lu Phytomedicine.2025; 141: 156654. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies Parag Jain, Akanksha Jain, Rohitas Deshmukh, Pradeep Samal, Trilochan Satapathy, Ajazuddin Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102584. CrossRef
Luteolin Relieves Metabolic Dysfunction-Associated Fatty Liver Disease Caused by a High-Fat Diet in Rats Through Modulating the AdipoR1/AMPK/PPARγ Signaling Pathway Pongsakorn Taweesap, Prapassorn Potue, Juthamas Khamseekaew, Metee Iampanichakul, Banyaphon Jan-O, Poungrat Pakdeechote, Putcharawipa Maneesai International Journal of Molecular Sciences.2025; 26(8): 3804. CrossRef
Association between non-skimmed milk consumption and metabolic dysfunction-associated fatty liver disease in US adults: insights from NHANES data Futao Wu, Fuying Zheng, Xue Li, Danzhu Wu, Honghao Li, Yingyi Zeng, Yan Tang, Side Liu, Aimin Li BMC Gastroenterology.2025;[Epub] CrossRef
Discovery of the first-in-class FABP/PPAR multiple modulator for the treatment of metabolic dysfunction-associated steatohepatitis Ya Chen, Zibin Liao, Jianming Mao, Wenxin Wang, Yuxia Liu, Wei Dai, Zheng Wen, Sishi Liu, Yayi Chen, Yiming Ma, Xiaoying Wang, Zheng Li European Journal of Medicinal Chemistry.2025; 291: 117635. CrossRef
Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives Chunyan Chen, Xiaolan Bu, Liping Deng, Jiayan Xia, Xinming Wang, Li Chen, Wen Li, Jie Huang, Qixiang Chen, Cheng Wang Frontiers in Pharmacology.2025;[Epub] CrossRef
Targeting Metabolism: Innovative Therapies for MASLD Unveiled Weixin Wang, Xin Gao, Wentong Niu, Jinping Yin, Kan He International Journal of Molecular Sciences.2025; 26(9): 4077. CrossRef
Unsupervised Test-Time Adaptation for Hepatic Steatosis Grading Using Ultrasound B-Mode Images Pedro Vianna, Paria Mehrbod, Muawiz Chaudhary, Michael Eickenberg, Guy Wolf, Eugene Belilovsky, An Tang, Guy Cloutier IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.2025; 72(5): 601. CrossRef
Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry and Network Pharmacology Reveal the Mechanisms of Rhodiola crenulata in Improving Non-Alcoholic Fatty Liver Disease Xin Zeng, Jianwei Wang, Qinyi Xu, Chengdan Deng, Xi Yi, Shang Wang, Ling Yao, Wei Xiang Current Issues in Molecular Biology.2025; 47(5): 324. CrossRef
Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease Hidenori Kido, Eishiro Mizukoshi, Masahiro Yanagi, Li Shihui, Takuya Seike, Hidetoshi Nakagawa, Tetsumori Yamashima, Yoshitake Shiraishi, Noriyuki Ozaki, Kenichi Harada, Hikari Okada, Hisanori Goto, Kumi Kimura, Yasuhiko Yamamoto, Taro Yamashita Journal of Gastroenterology.2025; 60(8): 990. CrossRef
Modulation of liver lipid metabolic pathways by central nervous system ER stress Han Rae Kim, Parisa Tabiatnejad, Hovhannes Arestakesyan, Colin N. Young American Journal of Physiology-Endocrinology and Metabolism.2025; 328(6): E833. CrossRef
Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia Marina Ribas Losasso, Maria Luiza Cesto Parussolo, Antony Oliveira Silva, Rosa Direito, Karina Quesada, Claudia Rucco Penteado Detregiachi, Marcelo Dib Bechara, Nahum Méndez-Sánchez, Ludovico Abenavoli, Adriano Cressoni Araújo, Ricardo de Alvares Goulart, International Journal of Molecular Sciences.2025; 26(10): 4673. CrossRef
Unveiling the role of IL7R in metabolism-associated fatty liver disease leading to hepatocellular carcinoma through transcriptomic and machine learning approaches Priyadharshini Annadurai, Arnold Emerson Isaac Discover Oncology.2025;[Epub] CrossRef
Managing Nonalcoholic Fatty Liver Disease Through Structured Lifestyle Modification Interventions Andrew Thomas, Annie Thomas American Journal of Lifestyle Medicine.2025;[Epub] CrossRef
Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease) Alexander A. Baranov, Galina V. Volynets, Nikolay N. Vlasov, Larisa G. Goryacheva, Margarita M. Gurova, Vera A. Greshnyakova, Anna N. Zaviyalova, Nina V. Evdokimova, Marina Yu. Komissarova, Leyla S. Namazova-Baranova, Valeriya P. Novikova, Elena V. Pavlov Pediatric pharmacology.2025; 22(2): 147. CrossRef
Association between organochlorine pesticides and metabolic dysfunction-associated steatotic liver disease: Findings from the Dongfeng-Tongji cohort Yi Guo, Xin Guan, Yutong You, Chengyong Jia, Yuhui Lin, Zhen Yin, Yu Yin, Guorong Zhong, Yuying Wen, Wenhui Li, Hui Zhao, Shengli Chen, Xi Wang, Xinlian Li, Xuanwen Mu, Pinpin Long, Hao Wang, Xiaomin Zhang, Meian He, Yu Yuan, Tao Jing, Huan Guo, Tangchun Environment International.2025; 201: 109571. CrossRef
KRT23 as a Potential Target for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): Evidence From Bioinformatics Analysis, Human Gene Polymorphism and Animal Experiments Yangmin Hao, Tao Zhang, Shaliyan Tuerxunmaimaiti, Ye Tian, Xinyu Wang, Zhiming Li, Liang Zhao, Lei Bai, Qu Chen, Cheng Li, Ayiguzhali Abulitipu, Rui Wang, Sheng Jiang, Guoli Du International Journal of General Medicine.2025; Volume 18: 2807. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
ECM formation and degradation during fibrosis, repair, and regeneration Alejandro E. Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, Joachim Høg Mortensen, Signe Holm Nielsen, Quentin M. Anstee, Arun J. Sanyal, Morten A. Karsdal, Detlef Schuppan npj Metabolic Health and Disease.2025;[Epub] CrossRef
The role of SIRT2 in homeostatic medicine and aging intervention Yue Li, Longchuan Han, Yinkun Fu, Yingting Zhang, Zhihui Zou, Jing Luo, Xinxin Tang, Lihong Tian, Yuheng Lu, Ying Huang, Ming He Oral Science and Homeostatic Medicine.2025; 1(1): 9610009. CrossRef
Integration of Metabolomics, Lipidomics, and Machine Learning for Developing a Biomarker Panel to Distinguish the Severity of Metabolic‐Associated Fatty Liver Disease Yanqiao Hui, Jiameng Qu, Junjie Yang, Hanwen Zhang, Chen Liang, Naixin Miao, Qian Zhang, Huarong Xu, Yiling Li, Qing Li Biomedical Chromatography.2025;[Epub] CrossRef
Prevalence and predictors of non‐alcoholic fatty liver disease (NAFLD) and metabolic dysfunction‐associated fatty liver disease (MAFLD) in Indian women with polycystic ovarian syndrome Aditi Rathi, Deepti Goswami, Anju Garg, Smita Kaushik, Niharika Dhiman Journal of Obstetrics and Gynaecology Research.2025;[Epub] CrossRef
The role of plasma glucose in association of food-specific serum immunoglobulin G reactivity with metabolic dysfunction-associated fatty liver disease: a real-world cross-sectional study Guanchao Sun, Wenjuan Wu, Binbin Su, Ru Zhang, Xiaoyu Dong, Lihui Wang, Shiping Xu, Hui Shi Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Medical Implications of Renaming Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Yu-Jin Choi, Chang-Gue Son Journal of Korean Medicine.2025; 46(2): 40. CrossRef
Serum uric acid/creatinine ratio and metabolic-associated fatty liver disease risks in children Bi Chen, Xiaoning Qu, Ting Li, Minghua Jiang Pediatric Research.2025;[Epub] CrossRef
The FMO3/TMAO/HSP90β axis aggravates MAFLD by disrupting mitochondrial protein homeostasis Jin Guo, Yukun Wang, Danmei Zhang, Chunxia Shi, Xiaoya Zhang, Xun Li, Zuojiong Gong Cellular Signalling.2025; 134: 111960. CrossRef
Anti-steatotic effect of Opuntia ficus-indica extracts rich in betalains and phenolics from fruit peel and pulp of different varieties in in vitro models Irene Besné-Eseverri, Jenifer Trepiana, Itziar Eseberri, Andrea Gómez-Maqueo, M. Pilar Cano, Joao Tomé-Carneiro, Alberto Dávalos, María P. Portillo Journal of Physiology and Biochemistry.2025; 81(4): 1305. CrossRef
Regulatory Mechanisms of Phenolic Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review Shengyu Zhang, Congcong Shen, Han Di, Yanhong Wang, Feng Guan Antioxidants.2025; 14(7): 760. CrossRef
Fatty liver index and risk of type 2 diabetes of adults with normoglycemia: Insights into insulin sensitivity and beta-cell function Ji Hyun Bae, Min Jin Lee, Su Hyun Kim, Joo Yeon Kim, Ah Reum Khang, Yang Ho Kang, Dongwon Yi, Guoying Wang PLOS One.2025; 20(6): e0327058. CrossRef
Loss of endothelial ZEB2 in mice attenuates steatosis early during metabolic dysfunction-associated steatotic liver disease Wouter Dheedene, Stefaan Verhulst, Louise Demuynck, Bram Callewaert, Willeke de Haan, Stefan Vinckier, Jore Van Wauwe, Petra Vandervoort, Marleen Lox, Mathias Stroobants, Renaud Lavend’homme, Wilfred F. J. van IJcken, Elizabeth A. V. Jones, An Zwijsen, Ma Scientific Reports.2025;[Epub] CrossRef
Prevalence of advanced liver fibrosis in the general population of the Paris region according to FIB-4 score and liver risk score Henri Tran, Stefano Caruso, Anne-Laure Mazialivoua, Cecile Fargeat, Odile Rousselet, Adrien Ko, Vincent Leroy, Patrick Ingiliz BMC Gastroenterology.2025;[Epub] CrossRef
TyG-BMI as a superior predictor of MAFLD and pre-MAFLD in Chinese adults: a cross-sectional study Xinru Huang, Yanyun Hu, Lining Dong, Liying Zhu, Jie Li, Ji Hu, Wei Shao, Yongde Peng, Fang Liu BMC Gastroenterology.2025;[Epub] CrossRef
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD Zhonghao Jiang, Baolin Qian, Tongjie Xu, Junjie Bai, Wenguang Fu ImmunoTargets and Therapy.2025; Volume 14: 719. CrossRef
The expanding role of semaglutide: beyond glycemic control Malek Zarei, Masoumeh Sabetkasaei, Masoud Mozafari, Sasan Zaeri Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Quantitative characterization of drug metabolism and transport alterations in obesity with metabolic fatty liver disease: A physiologically based pharmacokinetic modelling approach Yuewu Xie, Xiaoqin Bai, Chaozhuang Shen, Chaoran Xu, Chi Cui, Yujie Yang Journal of Pharmaceutical Sciences.2025; 114(9): 103906. CrossRef
Prevalencia e importancia de la enfermedad periodontal en pacientes con enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD) en Veracruz L. Roesch-Ramos, D.N. Guzmán-Uzcanga, S. Nolasco-Polito, S. Pérez-Pérez, F. Moreno-Marín, R.M. Francisco, H.R. Ordaz-Álvarez, F.B. Roesch-Dietlen, J.M. Remes-Troche, A.D. Cano-Contreras Revista de Gastroenterología de México.2025;[Epub] CrossRef
Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV Hui Wang, Yunqin Jiang, Shiyun Wang, Chanchan Lu, Lumin Tang, Tingting Gu, Shi Shu Acta Pharmaceutica.2025; 75(3): 309. CrossRef
Differential effects of sleep duration on cardiovascular risk in metabolic-associated fatty liver disease vs. without metabolic-associated fatty liver disease: evidence from National Health and Nutrition Examination Survey and Mendelian randomization Siyao Wang, Xinyi Liu, Jia He, Yihan Cui, Ai Jia European Journal of Gastroenterology & Hepatology.2025; 37(12): 1380. CrossRef
Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders Maria-Zinaida Dobre, Bogdana Virgolici, Ruxandra Cioarcă-Nedelcu Current Issues in Molecular Biology.2025; 47(7): 565. CrossRef
Shift in the urinary metabolome associated with 2,3,7,8-tetrachlorodibenzo-p-dioxin activation of the hepatic aryl hydrocarbon receptor Warren J. Sink, Russell Fling, Ali Yilmaz, Rance Nault, Delanie Goniwiecha, Jack R. Harkema, Stewart F. Graham, Tim Zacharewski Scientific Reports.2025;[Epub] CrossRef
Serum metabolites and gut microbiota mediate the causal link between anxiety and nonalcoholic fatty liver disease: a Mendelian randomization analysis Siyao Wang, Xinyi Liu, Jia He, Yihan Cui, Ai Jia European Journal of Gastroenterology & Hepatology.2025; 37(12): 1370. CrossRef
Gut microbiota as a metabolic mediator to prevent or attenuate MASLD Jing Luo, Yijiang Wei, Zhexin Fan, Baokun Li, Lingzhi Li, Yiwei Chai, Zihan Xing, Yingying Qiu, Wenwei Lu, Zhifeng Fang Critical Reviews in Food Science and Nutrition.2025; : 1. CrossRef
Applications of artificial intelligence in liver cancer: A scoping review Andrea Chierici, Fabien Lareyre, Antonio Iannelli, Benjamin Salucki, Sébastien Goffart, Lisa Guzzi, Elise Poggi, Hervé Delingette, Juliette Raffort Artificial Intelligence in Medicine.2025; 169: 103244. CrossRef
Soybean genistin-driven gut microbiota-derived butyrate synthesis activates the SIRT1 signaling pathway to ameliorate metabolic fatty liver Guohui Yi, Wanying Sun, Xueer Zhang, Zhongtao Wang, Xiaodan Yu, Canyang Zhu, Kaiwen Lin Free Radical Biology and Medicine.2025; 239: 336. CrossRef
Relación entre el control de la psoriasis y la enfermedad hepática esteatósica asociada a disfunción metabólica Citlalli Guadalupe Hernández Guzmán, Blanca Elena Verazaluce Rodríguez, Lauro Fabián Amador Medina, Graciela López Mata, Erick Josefat Díaz Huerta, Óscar Noel Chávez Hernández Piel.2025; 40(9): 558. CrossRef
MASLD vs. MAFLD. A narrative review Amedeo Lonardo, Ming-Hua Zheng, Mohammed Eslam Exploration of Digestive Diseases.2025;[Epub] CrossRef
Sweroside: unveiling broad therapeutic potential—from mechanistic insights to clinical potential Liu Peng, Man Zuo, Tian Qiu, Wenying Lan, Yue Wen, Xiao-Qin Ye Frontiers in Pharmacology.2025;[Epub] CrossRef
Mechanisms and Therapeutic Advances of PXR in Metabolic Diseases and Cancer Yuanbo Bi, Sifan Liu, Lei Wang, Daiyin Peng, Weidong Chen, Yue Zhang, Yanyan Wang International Journal of Molecular Sciences.2025; 26(16): 8029. CrossRef
Understanding MASLD — from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist Carlo Ratti, Mattia Malaguti, D'Aniello Emanuele, Antonio Bellasi, Gianluca Sanna Atherosclerosis.2025; 409: 120495. CrossRef
Global burden of NAFLD 1990–2021 and projections to 2035: Results from the Global Burden of Disease study 2021 Yuqin Mao, Jiqing Du, Baoguo Li, Jiong Wang, Shaoyan Xuan, Shu Yang, Zhihua Tang, Minxiu Wang, Hamidreza Karimi-Sari, PLOS One.2025; 20(8): e0330504. CrossRef
Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study Jungha Park, Jin-Wook Kim, Soo Lim Annals of Nutrition and Metabolism.2025; : 1. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review Marcelo do Rego Maciel Souto Maior, Nathália de Lacerda Interaminense Ribeiro, Hannah Vicentini Vitoriano Silva, Edmundo Pessoa Lopes, Emilia Chagas Costa Biomedicines.2025; 13(9): 2162. CrossRef
Association of Daily Steps with Incident Nonalcoholic Fatty Liver Disease: Evidence from the UK Biobank Cohort EVELYNNE S. FULDA, LAURA PORTAS, CHARLIE HARPER, DAVID PREISS, DERRICK BENNETT, AIDEN DOHERTY Medicine & Science in Sports & Exercise.2025; 57(9): 1905. CrossRef
Performance Assessment of ChatGPT-4.0 and ChatGLM Series in Traditional Chinese Medicine for Metabolic Associated Fatty Liver Disease: Comparative Study Xionghui Wang, Tianxiao Zheng, Bo Liu, Zhi Pei, Kaihan Meng, Changquan Ling JMIR Formative Research.2025; 9: e66503. CrossRef
Circulating ORM2 as a Biomarker of Metabolic Dysfunction: Evidence from the KADEM Study in Kuwaiti Adults Mohamed Abu-Farha, Ahmed N. Albatineh, Bader Alawadh, Loulwa Alsalem, Irina Al-Khairi, Preethi Cherian, Fahad Al-Ajmi, Mohammad Qaddoumi, Muhammad Abdul-Ghani, Fahd Al-Mulla, Jehad Abubaker International Journal of Molecular Sciences.2025; 26(17): 8326. CrossRef
Hic-5 deficiency attenuates MAFLD by inhibiting neutrophils migration via the CXCL1-CXCR2 axis Bingyu Ren, Han Li, Shenglu Liu, Zhiwei Huang, Junjie Bai, Zhonghao Jiang, Tongjie Xu, Boyuan Gu, Wenhao Yu, Lei Sun, Peng Tan, Wenguang Fu Journal of Gastroenterology.2025; 60(12): 1535. CrossRef
Association of exposure to phenols, pesticides, and phthalates with hepatic steatosis and MASLD in adolescents: the potential role of inflammation and lifestyle factors Xiaodie Yao, Cai Tang, Yu Li, Congwei You, Haoyang Zhang, Xiaohong Gu, Kerong Liu, Le Zhang Metabolism and Target Organ Damage.2025;[Epub] CrossRef
A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models Marialuisa de Ceglia, Rubén Tovar, Miguel Rodríguez-Pozo, Antonio Vargas, Ana Gavito, Juan Suárez, Elena Baixeras, Fernando Rodríguez de Fonseca, Juan Decara Biochemical Pharmacology.2025; 242: 117364. CrossRef
Association of elevated Alpha-1-Acid glycoprotein with MAFLD prevalence in young and middle-aged women: a cross-sectional study based on NHANES 2017–2020 Yi Xiao, Xian Luo, Yinghao Fu, Haijuan Huang, Qiaoping Gao, Jiansong Liu, Daxin Pang, Xiaolu Liang, Huadi Chen, Hao Xu Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Development of a nomogram model for predicting coronary heart disease in patients with metabolic-associated fatty liver disease Zhengliang Li, Xiaokai Chen, Juan Wang, Weirui Chen, Run Zhang, Lihua Cao, Shaoting Shi, Linlin Ren, Wenzhong Zhang Frontiers in Cardiovascular Medicine.2025;[Epub] CrossRef
In Silico Study of Natural Polyphenols as Potential Metabolic Modulators in Mitigating Lipotoxicity in Non-Alcoholic Fatty Liver Disease via Thyroid Hormone Receptor Alpha Activation Evangelia K. Konstantinou, Athanasios A. Panagiotopoulos, Maria Dimitriou Current Issues in Molecular Biology.2025; 47(9): 777. CrossRef
A Comprehensive Systematic Review on Therapeutic Discovery of NAFLD Drugs Sajja Keerthi Vathsalya, A. Gnanavel, N. Hima Bindu, S. Saravana Kumar, B. Naveen Kumar Research Journal of Pharmacy and Technology.2025; : 4564. CrossRef
Sugar-sweetened beverage consumption predicts metabolic associated fatty liver disease in patients with type 2 diabetes mellitus Zhenjun Yu, Mengdie Chen, Shicheng Gu, Chaohui Wang, Ping Feng, Gang Lin Frontiers in Endocrinology.2025;[Epub] CrossRef
Analysis of the Association Between TG/HDL, TyG, TyG-BMI, and ZJU Indices with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Yunyi Yang, Hongping Wang, Yanming He, Xiaoli He, Zheng Yao, Hongjie Yang Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3797. CrossRef
Analysis of subgingival microbial community structure in MAFLD patients with periodontitis Hai He, Jingli Zhu, Chuyi Li, Qisheng Shen, Jiarui Cao, Jinhai Ma, Zhenghu Feng, Zhiqiang Li, Tianzhu Song Clinical Oral Investigations.2025;[Epub] CrossRef
Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes Asiyeh Masaeli, Mohammad Taghi Goodarzi, Adel Mohammadalipour, Safa Ali-Asgari, Mohammad Reza Mirzaei, Mohsen Hani Scientific Reports.2025;[Epub] CrossRef
Nonlinear association between TyG-BMI and MAFLD: A cross-sectional study Qiuping Wang, Yuan Su, Jing Niu, Yan Wang, Liping Liu, Yanhong Hao, Qian Wu PLOS One.2025; 20(10): e0331140. CrossRef
Polycystic ovarian syndrome a risk factor for non-communicable diseases: insights into recent research and prevention approaches Iqra Naeem, Ayman Zehra, Faiza Rehman, Abid Hussain, Azhar Hussain, Nisar Hussain, Muhammad Waseem, Reem Mohammed Alqahtani, Ghalia Shamlan, Isam A. Mohamed Ahmed, Muhammad Faisal Manzoor, Muhammed Adem Abdullahi Journal of Ovarian Research.2025;[Epub] CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano Exploration of Medicine.2025;[Epub] CrossRef
Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu Frontiers in Nutrition.2025;[Epub] CrossRef
Perilipins: key targets for regulating lipid metabolism and alleviating abnormal lipid metabolism through exercise Yan-Jun Niu, Jing-Jing Liu, Jing-Hua Zhang, Shi-Qi Lu, Ke Wang, Zheng Zhu, Zhen-Bo Cao Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
CircRNA in Digestive Diseases: Recent Advances in Fundamental Mechanism and Clinical Potential Yuanye Ji, Shun Zhang, Ting Cai, Liyun Fu, Qinzhi Deng, Peng Zhu Current Molecular Medicine.2025; 25(9): 1107. CrossRef
Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis Marion Pradeau, Sandrine Beaulieu, Véronique Paquet, Jocelyn Trottier, Mélanie Verreault, Stéphanie Ferland, Olivier Barbier, Anne-Marie Carreau American Journal of Physiology-Endocrinology and Metabolism.2025; 329(5): E644. CrossRef
Analysis of risk factors associated with metabolic-associated fatty liver disease from Suzhong Region, China: a cross-sectional study Shuai Zhang, Hao Liang, Jun Liu, Ye Zhu BMJ Open.2025; 15(10): e096598. CrossRef
Predicting Metabolic Dysfunction–Associated Fatty Liver Disease Phenotypes Among Adults: 2-Stage Contrastive Learning Method Sizhe Jasmine Chen, Da Xu, Derek K Hu, Paul Jen-Hwa Hu, Ting-Shuo Huang JMIR Medical Informatics.2025; 13: e75747. CrossRef
Explainable machine learning model for classifying atherosclerotic cardiovascular disease in patients with metabolic dysfunction-associated steatotic liver disease Zhengliang Li, Xiaokai Chen, Linlin Ren, Banghui Wang, Shimiao Ruan, Juan Wang, Wenzhong Zhang Frontiers in Endocrinology.2025;[Epub] CrossRef
PGC-1α regulates lipid accumulation by coordinating fatty acid synthesis and oxidation in goose fatty liver Jiahui Li, Mengqing Lv, Long Liu, Tuoyu Geng, Daoqing Gong, Minmeng Zhao Poultry Science.2025; 104(12): 106052. CrossRef
Association of vitamin D levels with metabolic dysfunction-associated fatty liver disease in children aged 12–18 years Xuejie Gao, Yuyun Chen, Xinrui Wang, Yuehang Chen, Xiaoyan Chen, Haibo Li, Hong Ye Frontiers in Nutrition.2025;[Epub] CrossRef
Bifidobacterium bifidum enhances hepatic mitochondrial β-oxidation and ameliorates MAFLD in a high-fat diet rat model Fatemeh Dashti, Ava Bolandparvaz, Anahita Panji, Zahra Hojatifar, Mahdi Alinejad, Mahtab Mehboodi, Mohammad Hassan Maleki, Afsaneh Mirshekari, Elham Nadimi Scientific Reports.2025;[Epub] CrossRef
Betulinic acid as a novel AT1R inhibitor: attenuation of liver fibrosis via modulation of endothelial–mesenchymal transition in chronic hepatic injury Bingwen Zhu, Xiyu Dai, Chunyan Liu, Tao Bi, Shenglu Liu, Lei Chen, Ting Wang, Qixin Zhao, Xinyue Liu, Qin Sun, Yingcheng Yang, Zengjin Liu Journal of Translational Medicine.2025;[Epub] CrossRef
Qushi Huayu decoction alleviates NAFLD in mice by regulating gut microbiota homeostasis in the gut-liver axis via the pregnane X receptor Yuan Xu, Yiming Ni, Mingmei Zhou, Xiaojun Gou European Journal of Pharmacology.2025; 1008: 178366. CrossRef
Serum Extracellular Vesicles as Pathogenetic Signals in Obese and Lean Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Chi-Yi Chen, Che-Yu Hsu, Wei-Pang Chung, Hung-Yu Sun, Tzu-Ching Kao, Tzu-Yi Chen, Xing-Min Li, Wei-Lung Huang, Kung-Chia Young Metabolites.2025; 15(11): 746. CrossRef
Harnessing serum VOCs and machine learning for the early detection of MAFLD Xin Li, Xiaoyue Zhao, Ruonan Zhang, Xuewei Zhuang Frontiers in Endocrinology.2025;[Epub] CrossRef
Diabetes mellitus and liver: Non-obvious aspects A. O. Bueverov, E. L. Bueverova FOCUS. Endocrinology.2025; 6(3): 41. CrossRef
The role of hepatic steatosis Index, fatty liver Index, and metabolic and hormonal biomarkers in differentiating MASLD in polycystic ovary syndrome Enes Ucgul, Burak Menekse, Huseyin Demirci, Erman Cakal Journal of Endocrinological Investigation.2025;[Epub] CrossRef
К эпидемиологии жировой болезни печени, связанной с метаболической дисфункцией (систематический обзор литературы)
Вера Людвиговна Грицинская, Валерия Павловна Новикова Children's medicine of the North-West.2025; 13(3): 108. CrossRef
Associations between composite systemic inflammation indicators(CAR, CLR, SII, AISI, SIRI, and CALLY) and metabolic dysfunction-associated fatty liver disease (MAFLD): evidence from a two-stage study in China Jing Zhao, Quan Zhou, Yun Wang, Fangfei Xie, Jingyi Fan Frontiers in Immunology.2025;[Epub] CrossRef
Betaine Attenuates High‐Fat‐Diet‐Induced Metabolism‐Associated Steatotic Liver Disease via the Inhibition of Ferroptosis Through the Nrf2/GPX4 Axis Xiao‐jun Zhai, Cheng Xiao, Chun‐ru Yang, Ze‐rui Ding, Dong‐mei Wang, Jie‐ying Liu, Yu Miao The FASEB Journal.2025;[Epub] CrossRef
Regulatory Role of Nuclear Factor of Activated T Cells c4 in the Development of Metabolic dysfunction-associated Fatty Liver Disease Tong Shen, Jia Chen, Luyao Li, Guohao Li, Qianyu Guo, Meie Liang, Quanhai Pang Current Atherosclerosis Reports.2025;[Epub] CrossRef
Leucine Alleviates Endoplasmic Reticulum–Stress Mediated Lipotoxic Injury Induced by High-Fat Diet Via Sar1b/Sestrin2/Ampkα1 Pathways in Acanthopagrus Schlegelii Wenli Zhao, Yuedong Shen, Xuan Wang, Yangguang Bao, Óscar Monroig, Tingting Zhu, Xie Shichao, Peng Sun, Douglas R Tocher, Qicun Zhou, Min Jin The Journal of Nutrition.2025; : 101258. CrossRef
MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action Thong Duy Vo, Huong Tu Lam Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
Lactobacillus gasseri TF08-1 ameliorates high-fat diet induced nonalcoholic fatty liver disease and regulates gut microbiota in mice Qianyue Xu, Ningning He, Yu Tian, Zhinan Wu, Haoyu Wang, Bei Liu, Zizhen Yang, Haifeng Zhang, Qiang Luo, Yiyi Zhong, Liang Xiao, Shangyong Li, Yuanqiang Zou Journal of Applied Microbiology.2025;[Epub] CrossRef
Traditional Chinese medicine for non-alcoholic fatty liver disease: an overview of systematic reviews with evidence mapping and metabolic outcome assessment Juanjuan Li, Ruimin Jiao, Wenquan Su, Wei Chen, Xiangyu Hu, Shuai Xu, Lie Xu, Weiwei Yao, Kejia Liu, Hong You, Jingjie Zhao Frontiers in Pharmacology.2025;[Epub] CrossRef
Impact of Polyphenol Supplementation on Energy Expenditure Measured by Indirect Calorimetry in Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Study Christine Haïkal, Marie-Catherine Turcotte, Véronique Bélanger, Sophia Morel, Anik Cloutier, Emile Levy, Valérie Marcil, Ramy El-Jalbout, Véronique Groleau Healthcare.2025; 13(24): 3215. CrossRef
Research Progress on the Role and Mechanism of Flavonoids in Improving Metabolic Associated Fatty Liver Disease Lala Qin, Qingsong Xiao, Xin Deng Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4597. CrossRef
STEATOTIC LIVER DISEASE: THE IMPACT OF TEA AND COFFEE CONSUMPTION. LITERATURE REVIEW
V.S. Rakhmetova Наука и здравоохранение.2025; (5(27)): 261. CrossRef
Pre-MASLD: Should it be defined separately? Hang-Kai Huang, You-Ming Li, Cheng-Fu Xu Hepatobiliary & Pancreatic Diseases International.2024; 23(1): 1. CrossRef
Object detection: A novel AI technology for the diagnosis of hepatocyte ballooning Tian‐Lei Zheng, Jun‐Cheng Sha, Qian Deng, Shi Geng, Shu‐Yuan Xiao, Wen‐Jun Yang, Christopher D. Byrne, Giovanni Targher, Yang‐Yang Li, Xiang‐Xue Wang, Di Wu, Ming‐Hua Zheng Liver International.2024; 44(2): 330. CrossRef
Steatotic liver disease, MASLD and risk of chronic kidney disease Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher Diabetes & Metabolism.2024; 50(1): 101506. CrossRef
Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in mice Jinuk Seo, Doyoung Kwon, Sou Hyun Kim, Mi Ran Byun, Yun-Hee Lee, Young-Suk Jung Current Research in Food Science.2024; 8: 100663. CrossRef
Taohe Chengqi decoction alleviated metabolic-associated fatty liver disease by boosting branched chain amino acids catabolism in the skeletal muscles of type 2 diabetes mellitus Ziqiao Yuan, Hui Qiao, Ziwei Wang, Haoran Wang, Mingru Han, Wenzhou Zhang, Yang Zhou, Hozeifa Mohamed Hassan, Wen Zhao, Tingting Qin Phytomedicine.2024; 126: 155315. CrossRef
Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice Hassam Ali, Muhammad Shahzil, Vishali Moond, Maria Shahzad, Abhay Thandavaram, Alina Sehar, Haniya Waseem, Taha Siddiqui, Dushyant Singh Dahiya, Pratik Patel, Hans Tillmann Journal of Personalized Medicine.2024; 14(1): 61. CrossRef
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim Metabolism.2024; 152: 155789. CrossRef
Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini Metabolites.2024; 14(1): 52. CrossRef
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef
Time-restricted eating and supervised exercise for improving hepatic steatosis and cardiometabolic health in adults with obesity: protocol for the TEMPUS randomised controlled trial Alba Camacho-Cardenosa, Antonio Clavero-Jimeno, Juan J Martin-Olmedo, Francisco Amaro-Gahete, Rocío Cupeiro, María Trinidad González Cejudo, Patricia Virginia García Pérez, Carlos Hernández-Martínez, Raquel Sevilla-Lorente, Alejandro De-la-O, Alejandro Ló BMJ Open.2024; 14(1): e078472. CrossRef
Association of sex-specific body mass index and waist circumference trajectories with non-alcoholic fatty liver disease incidence based on growth mixture modeling Tengrui Cao, Chao Tong, Qiang Li, Yumei Han, Aheyeerke Halengbieke, Xuetong Ni, Bo Gao, Deqiang Zheng, Xinghua Yang Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(5): 1245. CrossRef
Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components Dongsheng Ran, ChunLing Xin, Yingcai Ma, Yanyan Lu Clinics and Research in Hepatology and Gastroenterology.2024; 48(3): 102302. CrossRef
A Cross-Sectional Investigation for Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease in Tibetan College Students in Mainland 娟 周 Advances in Clinical Medicine.2024; 14(02): 2843. CrossRef
The Global Epidemic of Metabolic Fatty Liver Disease Ethan C. Z. Lee, Vickram V. Anand, Alex C. Razavi, Pamela L. Alebna, Mark D. Muthiah, Mohammad S. Siddiqui, Nicholas W. S. Chew, Anurag Mehta Current Cardiology Reports.2024; 26(4): 199. CrossRef
Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review) Jiaqin Gao, Bin Zuo, Yang He Molecular Medicine Reports.2024;[Epub] CrossRef
Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration Evgenia Koureta, Evangelos Cholongitas Frontiers in Pharmacology.2024;[Epub] CrossRef
Association between remnant cholesterol and insulin resistance levels in patients with metabolic-associated fatty liver disease Shuang Wang, Qiang Zhang, Bo Qin Scientific Reports.2024;[Epub] CrossRef
Identification of crosstalk genes relating to ECM‐receptor interaction genes in MASH and DN using bioinformatics and machine learning Chao Chen, Yuxi He, Ying Ni, Zhanming Tang, Wensheng Zhang Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, Terry Cheuk‐Fung Yip, Grace Lai‐Hung Wong, Pei‐Wu Zhu, Sui‐Dan Chen, Morten Karsdal, Diana Julie Leeming, Pei Jiang, Cong Wang, Qiang Chen, Christopher D. Byrne, Giovanni Targher, Mohammed Eslam, Jacob Georg Liver International.2024; 44(5): 1129. CrossRef
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin Heliyon.2024; 10(5): e27325. CrossRef
Association of multiple serum minerals and vitamins with metabolic dysfunction-associated fatty liver disease in US adults: National Health and Nutrition Examination Survey 2017–2018 Peisen Guo, Jiahui Yu Frontiers in Nutrition.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo Frontiers in Nutrition.2024;[Epub] CrossRef
Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study Yu Kong, Zhongcai Yao, Lingli Ren, Liqin Zhou, Jinkai Zhao, Yuanyuan Qian, Dayong Lou Frontiers in Psychiatry.2024;[Epub] CrossRef
A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLD Zhonglin Li, Rui Gong, Huikuan Chu, Junchao Zeng, Can Chen, Sanping Xu, Lilin Hu, Wenkang Gao, Li Zhang, Hang Yuan, Zilu Cheng, Cheng Wang, Meng Du, Qingjing Zhu, Li Zhang, Lin Rong, Xiaoqing Hu, Ling Yang Atherosclerosis.2024; 392: 117526. CrossRef
Hydroxytyrosol Linoleoyl Ether Ameliorates Metabolic-Associated Fatty Liver Disease Symptoms in Obese Zucker Rats Rubén Tovar, Marialuisa de Ceglia, Miguel Rodríguez-Pozo, Antonio Vargas, Ana Gavito, Juan Suárez, Anna Boronat, Rafael de la Torre, Fernando Rodríguez de Fonseca, Elena Baixeras, Juan Decara ACS Pharmacology & Translational Science.2024; 7(5): 1571. CrossRef
Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study Lin Tuo, Li-ting Yan, Yi Liu, Xing-xiang Yang Frontiers in Endocrinology.2024;[Epub] CrossRef
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective Yansong Fu, Zhipeng Wang, Hong Qin Metabolites.2024; 14(4): 218. CrossRef
Evidence related to a vegetarian diet and metabolic dysfunction-associated steatotic liver disease: protocol for a scoping review Kasey Moss, Victor Gitman, M Ines Pinto Sanchez, Simon Oczkowski, David Armstrong, Saumya Jayakumar, Constantine Jason Karvellas, Nazia Selzner, Joanna Dionne BMJ Open.2024; 14(4): e079750. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Liver Cancer.2024; 13(5): 561. CrossRef
Prevalence of Nonalcoholic Fatty Liver Disease [NAFLD] and Metabolic dysfunction associated Fatty Liver Disease [MAFLD] in patients with Irritable Bowel Syndrome [IBS] Md. Musab Khalil, Sirajam Munira, Md. Mahbubul Alam, Al Mahmood Appolo, Musatafa Md. Abu Sayeed, Atikul Islam, Narwana Khaleque, Mohammad Faisal, Arifa Tasnim, Ruma Najnin, Mahmudur Rahman, Enamul Karim, Md. Golam Kibria SN Comprehensive Clinical Medicine.2024;[Epub] CrossRef
Positive association between insulin resistance and fatty liver disease in psoriasis: evidence from a cross-sectional study Xiaoyuan Zhong, Dawei Huang, Rongfen Chen, Lingling Yao, Rui Ma, Yingyuan Yu, Yuxiong Jiang, Luyang Kong, Jiajing Lu, Ying Li, Yuling Shi Frontiers in Immunology.2024;[Epub] CrossRef
Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population Young Lee, Eun Ju Cho, Eun Kyung Choe, Min-Sun Kwak, Jong In Yang, Seung-Won Oh, Jeong Yoon Yim, Goh Eun Chung Scientific Reports.2024;[Epub] CrossRef
Essential Oils for the Treatment and Management of Nonalcoholic Fatty Liver Disease (NAFLD) Taehwa Kim, Mohammad Al Mijan, Jeonga Lee, Jungmi Yun, Jae Heun Chung, Soo Min Son, Ryuk Jun Kwon Natural Product Communications.2024;[Epub] CrossRef
The Role of PNPLA3_rs738409 Gene Variant, Lifestyle Factors, and Bioactive Compounds in Nonalcoholic Fatty Liver Disease: A Population-Based and Molecular Approach towards Healthy Nutrition Meiling Liu, Sunmin Park Nutrients.2024; 16(8): 1239. CrossRef
Prevalence of metabolic dysfunction-associated fatty liver disease and its association with glycemic control in persons with type 2 diabetes in Africa: A systematic review and meta-analysis Emmanuel Ekpor, Samuel Akyirem, Precious Adade Duodu, Bert B. Little PLOS Global Public Health.2024; 4(5): e0002835. CrossRef
Role of FXR in the development of NAFLD and intervention strategies of small molecules Jiachan Long, Yuanhang Xu, Xuerong Zhang, Bingxing Wu, Caiyan Wang Archives of Biochemistry and Biophysics.2024; 757: 110024. CrossRef
Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum Josep León-Mengíbar, Enric Sánchez, Ferrán Herrerías, Mari Cruz De La Fuente, Maite Santamaría, José Manuel Valdivielso, Marcelino Bermúdez-López, Eva Castro, Judit Pallarés, Xavier Matias-Guiu, Felip Vilardell, Assumpta Caixàs, Marta Bueno, Raquel Martí, Frontiers in Endocrinology.2024;[Epub] CrossRef
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective Shelley E. Keating, Yogesh Chawla, Arka De, Elena S. George Hepatology International.2024; 18(S2): 959. CrossRef
Early life exposure to vitamin D deficiency impairs molecular mechanisms that regulate liver cholesterol biosynthesis, energy metabolism, inflammation, and detoxification Megan M. Knuth, Jing Xue, Marwa Elnagheeb, Raad Z. Gharaibeh, Sarah A. Schoenrock, Susan McRitchie, Cory Brouwer, Susan J. Sumner, Lisa Tarantino, William Valdar, R. Scott Rector, Jeremy M. Simon, Folami Ideraabdullah Frontiers in Endocrinology.2024;[Epub] CrossRef
Deconvolution analysis identified altered hepatic cell landscape in primary sclerosing cholangitis and primary biliary cholangitis Hoang Nam Pham, Linh Pham, Keisaku Sato Frontiers in Medicine.2024;[Epub] CrossRef
Letter to the editor: Comment on “The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – A four-arm randomized controlled trial” Luping Quan, Chao Ding, Yumeng Jin, Yaping Li Clinical Nutrition.2024; 43(6): 1595. CrossRef
Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case–control study and serological comparison Zheng Lin, Yue-yi Shi, Lu-yan Yu, Chen-xi Ma, Si-yi Pan, Yuan Dou, Qiu-jun Zhou, Yi Cao Frontiers in Medicine.2024;[Epub] CrossRef
Age at menopause and risk of metabolic dysfunction-associated fatty liver disease: A 14-year cohort study Ehn-Young Kim, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee Digestive and Liver Disease.2024; 56(11): 1880. CrossRef
MAFLD and glomerular hyperfiltration in subjects with normoglycemia, prediabetes and type 2 diabetes: A cross‐sectional population study Manuela Abbate, Aneliya Parvanova, Ángel Arturo López‐González, Aina M. Yañez, Miquel Bennasar‐Veny, José Ignacio Ramírez‐Manent, Elia Reseghetti, Piero Ruggenenti Diabetes/Metabolism Research and Reviews.2024;[Epub] CrossRef
Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017–2018 Yuxiao Zhang, Min Zhang, Shanjiamei Jiang, Heng Hu, Xinzhi Wang, Fan Yu, Yue’e Huang, Yali Liang Cancer Causes & Control.2024; 35(9): 1271. CrossRef
Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies Pegah Golabi, Soroor Owrangi, Zobair M. Younossi Alimentary Pharmacology & Therapeutics.2024;[Epub] CrossRef
Azorella compacta Organic Extracts Exacerbate Metabolic Dysfunction-Associated Fatty Liver Disease in Mice Fed a High-Fat Diet Jessica Zúñiga-Hernandez, Matías Quiñones San Martin, Benjamín Figueroa, Ulises Novoa, Francisco A. Monsalve, Mitchell Bacho, Aurelio San-Martin, Daniel R. González Pharmaceuticals.2024; 17(6): 746. CrossRef
Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β Joey A. Muns, Erik Schooten, Rychon D. J. van Dasselaar, Yvet E. Noordman, Kevin Adamzek, Arthur C. Eibergen, Sebas D. Pronk, Sagel Cali, Niels J. Sijbrandi, Eugen Merkul, Sabrina Oliveira, Paul M.P. van Bergen en Henegouwen, R. Bart Takkenberg, Joanne Ve European Journal of Nuclear Medicine and Molecular Imaging.2024; 51(12): 3545. CrossRef
Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD Jin Imai, Shinji Takashimizu, Nana Suzuki, Kana Ohshinden, Kana Sawamoto, Yusuke Mishima, Kota Tsuruya, Yoshitaka Arase, Mitsuhiko Yamano, Noriaki Kishimoto, Chizumi Yamada, Nagamu Inoue, Kengo Moriyama, Akiyasu Baba, Hidekazu Suzuki, Tatehiro Kagawa, Yas Scientific Reports.2024;[Epub] CrossRef
Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine Giancarlo Suffredini, Wei Dong Gao, Jeffrey M. Dodd-o Journal of Clinical Medicine.2024; 13(13): 3633. CrossRef
Importance of the gut microbiota in the gut-liver axis in normal and liver disease Stanislav Kotlyarov World Journal of Hepatology.2024; 16(6): 878. CrossRef
Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea Yu-Jin Kwon, Ja-Eun Choi, Kyung-Won Hong, Ji-Won Lee Journal of Translational Medicine.2024;[Epub] CrossRef
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef
Breaking Barriers: Enhancing Statins Utilization for Cardiovascular Protection in MAFLD Faraz Arshad The American Journal of Medicine.2024; 137(7): e142. CrossRef
Insight into the regulatory mechanism of m6A modification: From MAFLD to hepatocellular carcinoma Xuan Zha, Zewei Gao, Min Li, Xueli Xia, Zhenwei Mao, Shengjun Wang Biomedicine & Pharmacotherapy.2024; 177: 116966. CrossRef
Alanine aminotransferase predicts incident steatotic liver disease of metabolic etiology: Long life to the old biomarker! Amedeo Lonardo World Journal of Gastroenterology.2024; 30(24): 3016. CrossRef
Proinflammatory interleukins 2, 6 and tumor necrosis factor alpha in patients with hypertension and diabetes mellitus depending on the presence of metabolic-associated liver steatosis O.M. Radchenko, O.J. Komarytsia, M.O. Borovets, R.S. Ivasivka, R.R. Guta INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(3): 200. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Gastroenterology.2024; 84(1): 1. CrossRef
Disinfection Byproducts of Haloacetaldehydes Disrupt Hepatic Lipid Metabolism and Induce Lipotoxicity in High-Fat Culture Conditions Lili Yang, Zhiqiang Jiang, Lan Yang, Weiwei Zheng, Yu Chen, Fei Qu, M. James C. Crabbe, Yubin Zhang, Melvin E. Andersen, Yuxin Zheng, Weidong Qu Environmental Science & Technology.2024; 58(28): 12356. CrossRef
Association between life’s essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults Zheng Wang, Bohan Huang, Yixuan Ding, Feng Cao, Fei Li, Prof Fei Li Archives of Public Health.2024;[Epub] CrossRef
Metformin Lowers Plasma Triacylglycerol Levels in Mice with Impaired Carnitine Biosynthesis and Fatty Liver Bodil Bjørndal, Tra-My Thi Le, Elin Strand, Lise Madsen, Rolf K. Berge SynBio.2024; 2(3): 240. CrossRef
The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review Kiana Mohammadian, Fatemeh Fakhar, Shayan Keramat, Agata Stanek Antioxidants.2024; 13(7): 797. CrossRef
Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease Mohammadjavad Sotoudeheian Protein & Peptide Letters.2024; 31(4): 290. CrossRef
In vitro osteoclast differentiation enhanced by hepatocyte supernatants from high-fat diet mice Yan Wang, Fangli Zhou, Siyi Shu, Yunhong Wu, Haoming Tian, Yujue Li, Xiang Chen Biochemistry and Biophysics Reports.2024; 39: 101788. CrossRef
Novel insights into autophagy in gastrointestinal pathologies, mechanisms in metabolic dysfunction-associated fatty liver disease and acute liver failure Tsvetelina Velikova, Milena Gulinac World Journal of Gastroenterology.2024; 30(27): 3273. CrossRef
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review Liana Iordan, Laura Gaita, Romulus Timar, Vlad Avram, Adrian Sturza, Bogdan Timar International Journal of Molecular Sciences.2024; 25(13): 7057. CrossRef
Genotypic variation in CYP2E1, GCKR, and PNPLA3 among nonalcoholic steatohepatitis patients of Turkish origin Abbas Ali Husseini Molecular Biology Reports.2024;[Epub] CrossRef
Hepatic Steatosis Can Be Partly Generated by the Gut Microbiota–Mitochondria Axis via 2-Oleoyl Glycerol and Reversed by a Combination of Soy Protein, Chia Oil, Curcumin and Nopal Mónica Sánchez-Tapia, Sandra Tobón-Cornejo, Lilia G. Noriega, Natalia Vázquez-Manjarrez, Diana Coutiño-Hernández, Omar Granados-Portillo, Berenice M. Román-Calleja, Astrid Ruíz-Margáin, Ricardo U. Macías-Rodríguez, Armando R. Tovar, Nimbe Torres Nutrients.2024; 16(16): 2594. CrossRef
TG: HDL, AST: ALT, A:G Ratios in Alcoholic and Non-alcoholic Fatty Liver patients Abhinav Manish, Anuradha Bharosay, Kanchan Negi, Ritesh Srivastava Journal of Research in Applied and Basic Medical Sciences.2024; 10(3): 279. CrossRef
Protective effects of syringic acid in nonalcoholic fatty liver in rats through regulation of Nrf2/HO‐1 signaling pathway Simiao Zhang, Sheng Zheng, Ya Li, Juan Yang, Xiaozhou Mao, Tao Liu, Qiuxin Zhang, ZhiPeng Fu, Xing Zhu, Long Xu Journal of Biochemical and Molecular Toxicology.2024;[Epub] CrossRef
SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis Ileana Mendez Espinoza, Elijah N. D. Choos, Carolyn M. Ecelbarger, Blythe D. Shepard American Journal of Physiology-Gastrointestinal and Liver Physiology.2024; 327(2): G235. CrossRef
Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation Hiroki Yanagisawa, Hitoshi Maeda, Isamu Noguchi, Motohiko Tanaka, Naoki Wada, Taisei Nagasaki, Kazuki Kobayashi, Gai Kanazawa, Kazuaki Taguchi, Victor Tuan Giam Chuang, Hiromi Sakai, Hiroyuki Nakashima, Manabu Kinoshita, Hiroaki Kitagishi, Yasuko Iwakiri, Redox Biology.2024; 76: 103314. CrossRef
Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD I Sabinari, O Horakova, T Cajka, V Kleinova, MR Wieckowski, M Rossmeisl Physiological Research.2024; (Suppl 1): S295. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Medicine.2024; 99(4): 189. CrossRef
Effect of Ilex hainanensis Merr. On HFD-induced nonalcoholic fatty liver disease and rebalance of gut microbiota and bile acids metabolism in mice Jia-yi Tian, Meng Xiao, Wen-wen Zhao, Xia Wu, Jie Yang, Xiao-qing Chen Fitoterapia.2024; 178: 106186. CrossRef
The interplay of extracellular vesicles in the pathogenesis of metabolic impairment and type 2 diabetes Lorenzo Carciero, Gianfranco Di Giuseppe, Eleonora Di Piazza, Erfan Parand, Laura Soldovieri, Gea Ciccarelli, Michela Brunetti, Antonio Gasbarrini, Enrico C. Nista, Giovambattista Pani, Alfredo Pontecorvi, Andrea Giaccari, Teresa Mezza Diabetes Research and Clinical Practice.2024; 216: 111837. CrossRef
Additive effect of metabolic dysfunction-associated fatty liver disease on left ventricular function and global strain in type 2 diabetes mellitus patients: a 3.0 T cardiac magnetic resonance feature tracking study Xin Tang, Rui Shi, Li Jiang, Wei-Feng Yan, Pei-Lun Han, Wen-Lei Qian, Zhi-Gang Yang, Yuan Li Cardiovascular Diabetology.2024;[Epub] CrossRef
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef
Asperuloside activates hepatic NRF2 signaling to stimulate mitochondrial metabolism and restore lipid homeostasis in high fat diet-induced MAFLD Chufeng He, Qile Zhang, Ruiwen Zhu, Gary Tse, Wing Tak Wong European Journal of Pharmacology.2024; 983: 177003. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
3,5-Dimethyl-2,4,6-trimethoxychalcone Lessens Obesity and MAFLD in Leptin-Deficient ob/ob Mice Stéphanie Gaigé, Anne Abysique, Rym Barbouche, Alain Tonetto, Attilio Di Maio, Maxime Robin, Anh-Tuan Lormier, Jean-Denis Troadec International Journal of Molecular Sciences.2024; 25(18): 9838. CrossRef
Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease Oswald Quehenberger, Aaron M. Armando, Tiffany H. Cedeno, Rohit Loomba, Arun J. Sanyal, Edward A. Dennis Journal of Lipid Research.2024; 65(10): 100647. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung Cancers.2024; 16(18): 3161. CrossRef
Comprehensive RNA-Seq Gene Co-Expression Analysis Reveals Consistent Molecular Pathways in Hepatocellular Carcinoma across Diverse Risk Factors Nicholas Dale D. Talubo, Po-Wei Tsai, Lemmuel L. Tayo Biology.2024; 13(10): 765. CrossRef
Tea intake and non-alcoholic fatty liver disease risk: A two-sample Mendelian randomization study Cuncun Lu, Lixin Ke, Alexios-Fotios A. Mentis, Qiang Zhang, Ziyi Wang, Zhifei Wang Metabolism Open.2024; 24: 100322. CrossRef
Significance of Immune and Non-Immune Cell Stroma as a Microenvironment of Hepatocellular Carcinoma—From Inflammation to Hepatocellular Carcinoma Progression Jacek Baj, Magdalena Kołodziej, Joanna Kobak, Jacek Januszewski, Kinga Syty, Piero Portincasa, Alicja Forma International Journal of Molecular Sciences.2024; 25(19): 10233. CrossRef
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review Haixiang Zheng, Leonardo Antonio Sechi, Eliano Pio Navarese, Gavino Casu, Gianpaolo Vidili Cardiovascular Diabetology.2024;[Epub] CrossRef
A new Korean nomenclature for steatotic liver disease
Clinical and Molecular Hepatology.2024; 30(Suppl): S214. CrossRef
Association of niacin intake and metabolic dysfunction-associated steatotic liver disease: findings from National Health and Nutrition Examination Survey Jing Zhou, Jun Han BMC Public Health.2024;[Epub] CrossRef
Impact of High-Temperature Feeds on Gut Microbiota and MAFLD Lijun Xue, Kaimin Li, Yanfei Jia, Dongxue Yao, Xuexing Guo, Shuhong Zhang Journal of Microbiology and Biotechnology.2024; 34(9): 1789. CrossRef
Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques Shivani R Kale, Geeta Karande, Anand Gudur, Aishwarya Garud, Monika S Patil, Satish Patil Cureus.2024;[Epub] CrossRef
Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease:
Detecting Advanced Fibrosis based on Reported Liver Stiffness
Measurement in FibroScan and Laboratory Findings Mohammadjavad Sotoudeheian The International Journal of Gastroenterology and Hepatology Diseases.2024;[Epub] CrossRef
Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis Ji Lee, Sue Kim, Yaeji Lee, Yu-Jin Kwon, Ji-Won Lee Nutrients.2024; 16(20): 3551. CrossRef
Day napping and metabolic-associated fatty liver disease: A systematic review and meta-analysis of observational studies Linxiao Gao, Jianping Gong, Guochao Zhong, Yajun Qin Medicine.2024; 103(44): e40362. CrossRef
Unbiased and reproducible liver MRI-PDFF estimation using a scan protocol-informed deep learning method Juan P. Meneses, Ayyaz Qadir, Nirusha Surendran, Cristobal Arrieta, Cristian Tejos, Marcelo E. Andia, Zhaolin Chen, Sergio Uribe European Radiology.2024; 35(5): 2843. CrossRef
Oxylipins Derived from PUFAs in Cardiometabolic Diseases: Mechanism of Actions and Possible Nutritional Interactions Duygu Ağagündüz, Özge Yeşildemir, Emine Koçyiğit, Tevfik Koçak, Buket Özen Ünaldı, Gamze Ayakdaş, Ferenc Budán Nutrients.2024; 16(22): 3812. CrossRef
Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022 Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang The Korean Journal of Internal Medicine.2024; 39(6): 931. CrossRef
ASPP2 deficiency promotes the progression of metabolic dysfunction-associated steatohepatitis via ACSL4 upregulation Jinming Wang, Quanwei Li, Yunfei Huo, Xiaoni Liu, Ying Shi, Bangxiang Xie Scientific Reports.2024;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won- Diabetes & Metabolism Journal.2024; 48(6): 1015. CrossRef
Exploring the relationship between air pollution, non-alcoholic fatty liver disease, and liver function indicators: a two-sample Mendelian randomization analysis study Qingliang Song, Jinyue Pan, Maoxing Pan, Chuiyang Zheng, Wen Fan, Jianwei Zhen, Dajin Pi, Zheng Liang, Haiyan Shen, Yuanyou Li, Qinhe Yang, Yupei Zhang Frontiers in Endocrinology.2024;[Epub] CrossRef
Western diet promotes the progression of metabolic dysfunction‐associated steatotic liver disease in association with ferroptosis in male mice Nicole Maddie, Nefia Chacko, David Matatov, Maria Alicia Carrillo‐Sepulveda Physiological Reports.2024;[Epub] CrossRef
Coriandrum sativum L. Leaf Extract Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating the AMPK Pathway in High Fat-Fed C57BL/6 Mice Min Ji Gu, Yejin Ahn, Yu Ra Lee, Guijae Yoo, Yoonsook Kim, Inwook Choi, Sang Keun Ha, Donghwan Kim Nutrients.2024; 16(23): 4165. CrossRef
Comparative analysis of NAFLD-related health videos on TikTok: a cross-language study in the USA and China Hongyu Wu, Jialun Peng, Shengwei Li, Xiong Ding, Tao Zhong, Qilong Zhai, Changjie Du, Jiajun Yuan, Can Cai, Jinzheng Li BMC Public Health.2024;[Epub] CrossRef
Metabolic syndrome therapy in pediatric age — between classic and modern. From diets to pipeline drugs Otilia Elena Frăsinariu, Vasile Valeriu Lupu, Laura Mihaela Trandafir, Violeta Streanga, Elena Jechel, Iris Bararu-Bojan, Ioana Vasiliu, Magdalena Cuciureanu, Isabela Ioana Loghin, Costica Mitrofan, Alin Horatiu Nedelcu, Anton Knieling, Ancuta Lupu Frontiers in Nutrition.2024;[Epub] CrossRef
Triglycerides to apolipoprotein A1 ratio: an effective insulin resistance-associated index in identifying metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus Wei Wang, Yang Chen, Mei Tu, Hang Ju Chen Frontiers in Endocrinology.2024;[Epub] CrossRef
Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies Wanghao Liu, Xiaoying Sun BMC Nephrology.2024;[Epub] CrossRef
Association between the ratio of serum uric acid to high-density lipoprotein cholesterol and liver fat content: evidence from a Chinese health examination dataset Ao Liu, Yongbing Sun, Xin Qi, Yang Zhou, Jing Zhou, Zhonglin Li, Xiaoling Wu, Zhi Zou, Xue Lv, Hao Li, Yongli Li Scientific Reports.2024;[Epub] CrossRef
Association of serum selenium with MASLD and liver fibrosis: A cross-sectional study Wenying Guo, Ting Weng, Yufei Song, Anna Di Sessa PLOS ONE.2024; 19(12): e0314780. CrossRef
Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Associati Magdalena Olszanecka-Glinianowicz, Artur Mazur, Jerzy Chudek, Beata Kos-Kudła, Leszek Markuszewski, Dominika Dudek, Piotr Major, Piotr Małczak, Wiesław Tarnowski, Paweł Jaworski, Elżbieta Tomiak Nutrients.2023; 15(7): 1641. CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski International Journal of Molecular Sciences.2023; 24(11): 9677. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef
Metabolic dysfunction: The silenced connection with fatty liver disease Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez Annals of Hepatology.2023; 28(6): 101138. CrossRef
MAFLD: an optimal framework for understanding liver cancer phenotypes Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George Journal of Gastroenterology.2023; 58(10): 947. CrossRef
Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease Chuan Lu, Yan Chen, Yue Zhang, Xin Zhao Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2627. CrossRef
Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease Rachmad Anres Dongoran, Fang-Cen Tu, Chin-Hung Liu Tzu Chi Medical Journal.2023; 35(4): 290. CrossRef
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk Keungmo Yang, Myeongjun Song Nutrients.2023; 15(18): 3970. CrossRef
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, Theocharis Koufakis, Ioannis G. Lempesis, Eleni Papantoniou, Georgios Kalopitas, Vasiliki E. Georgakopoulou, Ioanna E. Stergiou, Stamatios Theocharis, Georgios Germanidis International Journal of Molecular Sciences.2023; 24(19): 14704. CrossRef
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień Medicina.2023; 59(10): 1789. CrossRef
Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus Alessandro Csermely, Alessandro Mantovani, Mario Luca Morieri, Luisa Palmisano, Maria Masulli, Efisio Cossu, Marco Giorgio Baroni, Katia Bonomo, Flavia Agata Cimini, Gisella Cavallo, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Ro Diabetes & Metabolism.2023; 49(6): 101477. CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity Gi-Ae Kim, Joon Ho Moon, Won Kim Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials Ming-Lun Yeh, Ming-Lung Yu Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef
The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers Amedeo Lonardo Expert Review of Clinical Pharmacology.2023; 16(10): 891. CrossRef
Vascular calcification: from the perspective of crosstalk Shiqi Yang, Zhaolin Zeng, Qing Yuan, Qian Chen, Zuo Wang, Hui Xie, Jianghua Liu Molecular Biomedicine.2023;[Epub] CrossRef
What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez Current Hepatology Reports.2023; 22(4): 221. CrossRef
Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease Divyavani Gowda, Chandra Shekhar, Siddabasave Gowda B. Gowda, Yifan Chen, Shu-Ping Hui Livers.2023; 3(4): 687. CrossRef
Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver Decheng Meng, Fengxia Zhang, Wenfei Yu, Xin Zhang, Guoliang Yin, Pengpeng Liang, Yanan Feng, Suwen Chen, Hongshuai Liu Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4043. CrossRef
Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries Giuseppina Palladini, Laura Giuseppina Di Pasqua, Anna Cleta Croce, Andrea Ferrigno, Mariapia Vairetti International Journal of Molecular Sciences.2023; 24(24): 17407. CrossRef
Association between carotenoid intake and metabolic dysfunction-associated fatty liver disease among US adults: A cross-sectional study Hang Zhang, Li Li, Lei Jia, Jinchun Liu Medicine.2023; 102(51): e36658. CrossRef
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
Citations
Citations to this article as recorded by
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari, Journal of Clinical Medicine.2025; 14(2): 428. CrossRef
Exploring the Mechanism of Action of GLP-1RAs in the Treatment of Non-Alcoholic Fatty Liver Disease Combined with Diabetes Based on Network Pharmacology 高林 齐 Medical Diagnosis.2025; 15(02): 200. CrossRef
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease Roxana Liana Lucaciu, Sorina Cezara Coste, Adriana Corina Hangan, Mihaela Iancu, Olga Hilda Orășan, Angela Cozma, Sidonia Gog Bogdan, Lucia Maria Procopciuc International Journal of Molecular Sciences.2025; 26(12): 5717. CrossRef
High sensitivity C-reactive protein may be a significant predictor of non-alcoholic fatty liver disease in non-obese adults: A four-year retrospective study Changxi Chen, Jiande Gong, Mengting Li, Shiyu Pan, Guitao Xia, Yuemei Xu, Hongliang Li, Qi Lin Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(12): 104224. CrossRef
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk Alaa M. Mostafa, Ziyan Pan, Ming-Lung Yu, Necati Örmeci, Yasser Fouad, Mohammed Eslam Hepatic Medicine: Evidence and Research.2025; Volume 17: 75. CrossRef
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef
Current status and future trends of the global burden of MASLD Lei Miao, Giovanni Targher, Christopher D. Byrne, Ying-Ying Cao, Ming-Hua Zheng Trends in Endocrinology & Metabolism.2024; 35(8): 697. CrossRef
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong Obesity Reviews.2024;[Epub] CrossRef
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research E. V. Biryukova Meditsinskiy sovet = Medical Council.2024; (6): 72. CrossRef
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef
AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study Hai‐Yang Yuan, Xiao‐Fei Tong, Ya‐Yun Ren, Yang‐Yang Li, Xin‐Lei Wang, Li‐Li Chen, Sui‐Dan Chen, Xiao‐Zhi Jin, Xiao‐Dong Wang, Giovanni Targher, Christopher D. Byrne, Lai Wei, Vincent W.‐S Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming‐Hua Zheng Liver International.2024; 44(10): 2572. CrossRef
Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury Hewei Wei, Ting Zhao, Xinglong Liu, Qiteng Ding, Junran Yang, Xiaoyu Bi, Zhiqiang Cheng, Chuanbo Ding, Wencong Liu Molecules.2024; 29(15): 3537. CrossRef
Protective Effects of Plum on Liver and Gut Injury in Metabolic Dysfunction-Associated Fatty Liver Disease Ji-Su Kim, Sun-Mee Hong, Do-Kyun Kim, Young-Eun Cho Nutrients.2024; 16(21): 3760. CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection Tzu-I Chen, Fu-Jen Lee, Wan-Lun Hsu, Yong-Chen Chen, Mingchih Chen Cancers.2023; 15(4): 1148. CrossRef
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different? Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome David S. H. Bell, Terri Jerkins Diabetes, Obesity and Metabolism.2023; 25(11): 3093. CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha Cureus.2023;[Epub] CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD) Iryna Kostitska, Nadia Protas, Liliia Petrovska Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef
Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives Lei Miao, Giovanni Targher, Christopher D. Byrne, Luca Valenti, Xiaolong Qi, Ming‐Hua Zheng Portal Hypertension & Cirrhosis.2022; 1(1): 57. CrossRef
The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy Bo Yuan, Jichun Ma, Jing Wang, Jinyong Hao Frontiers in Endocrinology.2022;[Epub] CrossRef
Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng
Clin Mol Hepatol 2022;28(2):183-195. Published online November 28, 2021
Background/Aims Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers. Klotho, an enzyme encoded by the klotho (KL) gene in human, has been implicated in the pathogenesis of metabolic dysfunctions. However, the impact of variants in KL on NAFLD risk remains poorly understood. The aim of this study was to investigate the impact of KL rs495392 C>A polymorphism on the histological severity of NAFLD.
Methods We evaluated the impact of the KL rs495392 polymorphism on liver histology in 531 Chinese with NAFLD and replicated that in the population-based Rotterdam Study cohort. The interactions between the rs495392, vitamin D, and patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 polymorphism were also analyzed.
Result s: Carriage of the rs495392 A allele had a protective effect on steatosis severity (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.42–0.89; P=0.010) in Chinese patients. After adjustment for potential confounders, the A allele remained significant with a protective effect (OR, 0.66; 95% CI, 0.45–0.98; P=0.040). The effect on hepatic steatosis was confirmed in the Rotterdam Study cohort. Additional analysis showed the association between serum vitamin D levels and NAFLD specifically in rs495392 A allele carriers, but not in non-carriers. Moreover, we found that the rs495392 A allele attenuated the detrimental impact of PNPLA3 rs738409 G allele on the risk of severe hepatic steatosis.
Conclusions The KL rs495392 polymorphism has a protective effect against hepatic steatosis in patients with NAFLD.
Citations
Citations to this article as recorded by
Unraveling chemotherapy-evoked hepatic dysfunction: a deep dive into cyclophosphamide-related liver injury Ehab E. Sharata, Mina Ezzat Attya, Marwa M. Khalaf, Remon Roshdy Rofaeil, Ramadan A. M. Hemeida, Amira M. Abo-Youssef Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(2): 2097. CrossRef
Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation Sin Man Lam, Zehua Wang, Jin-Wen Song, Yue Shi, Wen-Yue Liu, Lin-Yu Wan, Kaibo Duan, Gek Huey Chua, Yingjuan Zhou, Guibin Wang, Xiahe Huang, Yingchun Wang, Fu-Sheng Wang, Ming-Hua Zheng, Guanghou Shui Cell Metabolism.2025; 37(1): 69. CrossRef
Levomilnacipran alleviates cyclophosphamide-induced hepatic dysfunction in male Wistar albino rats; emerging role of α-Klotho/TLR4/p38-MAPK/NF-κB p65 and caspase-3-driven apoptosis trajectories Ehab E. Sharata, Mina Ezzat Attya, Marwa M. Khalaf, Remon Roshdy Rofaeil, Amira M. Abo-Youssef, Ramadan A.M. Hemeida International Immunopharmacology.2025; 152: 114384. CrossRef
Apremilast attenuates methotrexate-induced hepatic injury in rats; insights into TLR4/NF-κB/P38 MAPK/caspase-3 and α-klotho/Nrf2/HO-1 signaling network interplay Reham H. Mohyeldin, Ehab E. Sharata, Mahmoud Abdelnaser, Ayman M. Ibrahim, Mina Ezzat Attya, Al Shaimaa Mahmoud Kotb, Ahmed S.Aboalela, Remon Roshdy Rofaeil Toxicology and Applied Pharmacology.2025; 505: 117596. CrossRef
Buspirone combats cyclophosphamide-provoked hepatotoxicity in rats via activation of AMPK/Nrf2/HO-1 and suppression of NF-κB p65 /NLRP3 inflammasome pathways Marwa M. Khalaf, Ehab E. Sharata, Waleed A. I. Khallaf, Mina Ezzat Attya, Amira M. Abo-Youssef, Ramadan A. M. Hemeida, Remon Roshdy Rofaeil Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub] CrossRef
The relationship of serum klotho levels and triglyceride glucose index-related indicators Yaoyao Zhou, Yaqi Wang, Fangli Li, Yiming Shi, Taotao Wu, Yingshuai Li Lipids in Health and Disease.2024;[Epub] CrossRef
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk Jacob Nysather, Eda Kaya, Paul Manka, Prakash Gudsoorkar, Wing-Kin Syn Advances in Kidney Disease and Health.2023; 30(4): 315. CrossRef
Emerging role of α-Klotho in energy metabolism and cardiometabolic diseases Yuanbin Liu, Mingkai Chen Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102854. CrossRef
Advances in genetic variation in metabolism-related fatty liver disease Fan Shi, Mei Zhao, Shudan Zheng, Lihong Zheng, Haiqiang Wang Frontiers in Genetics.2023;[Epub] CrossRef
Klotho Levels and Their Relationship with Inflammation and Survival among Alcoholic Patients Candelaria Martín-González, Elisa Espelosín-Ortega, Pedro Abreu-González, Camino Fernández-Rodríguez, Víctor Eugenio Vera-Delgado, Lourdes González-Navarrete, Alen García-Rodríguez, Antonio Martínez Riera, Emilio González-Reimers Biomolecules.2022; 12(8): 1151. CrossRef
CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice Rongrong Tan, Jiayang Li, Lu Liu, Qian Wu, Lei Fan, Ningning Ma, Chuwei Yu, Henglei Lu, Xuemei Zhang, Jing Chen, Likun Gong, Jin Ren International Journal of Molecular Sciences.2022; 23(24): 15931. CrossRef
Background/Aims Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. We aimed to investigate the usefulness of a key biomarker, lipocalin-2 (LCN2), for the detection of NASH progression.
Methods A mouse NASH model was established using a high-fat diet and a high-sugar drinking water. Gene expression profile of the NASH model was analyzed using RNA sequencing. Moreover, 360 NAFLD patients (steatosis, 83; NASH, 277), 40 healthy individuals, and 87 patients with alcoholic fatty liver disease were recruited.
Result s: Inflammatory infiltration, focal necrosis in the leaflets, steatosis, and fibrosis were documented in the mouse liver. In total, 504 genes were differentially expressed in the livers of NASH mice, and showed significant functional enrichment in the inflammation-related category. Upregulated liver LCN2 was found to be significantly interactive with various interleukins and toll-like receptors. Serum LCN2 levels were significantly increased in NAFLD patients. Serum LCN2 levels were correlated with steatosis, intralobular inflammation, semiquantitative fibrosis score, and nonalcoholic fatty liver disease activity score. The area under the curve of serum LCN2 was 0.987 with a specificity of 100% and a sensitivity of 93.5% for NASH diagnosis, and 0.977 with almost the same specificity and sensitivity for steatosis.
Conclusions LCN2 might be involved in the transition from NAFL to NASH by mediating inflammation. Serum LCN2 levels might be a novel biomarker for the diagnosis of NASH.
Citations
Citations to this article as recorded by
Mutation of PXR phosphorylation motif at Ser347 disrupts lipid and bile acid homeostasis in diet-induced metabolic dysfunction–associated steatohepatitis in mice Veronia Basaly, Zakiyah R. Henry, Rulaiha E. Taylor, Bo Kong, Ill Yang, Anita Brinker, Zhenning Yang, Peihong Zhou, Laurie B. Joseph, Lauren Aleksunes, Brian Buckley, Masahiko Negishi, Grace L. Guo Drug Metabolism and Disposition.2026; 54(2): 100222. CrossRef
A diet-driven metabolic dysfunction-associated steatohepatitis (MASH) mouse model resembles the corresponding human disease Guilherme Ribeiro Romualdo, Letícia C. Valente, Gabriel P. Bacil, Luana Riechelmann-Casarin, Antônio R. B. da Fonseca, Miguel W. Fornes, Luís F. Barbisan Journal of Molecular Histology.2025;[Epub] CrossRef
Role of Neutrophils in Homeostasis and Diseases Xingyu Chang, Yulin Liu, Junjun Qiu, Keqin Hua MedComm.2025;[Epub] CrossRef
The Role of an Elevated Fibrosis‐4 Index in Neurocognitive Decline and Brain Volume Reduction in Older Adults With Metabolic Dysfunction‐Associated Steatotic Liver Disease Maiko Nagaoka, Katsuya Nagaoka, Naoto Kajitani, Kazuhiro Yoshiura, Yoko Yoshimaru, Takehisa Watanabe, Hiroko Setoyama, Noboru Fujise, Minoru Takebayashi, Yasuhito Tanaka Geriatrics & Gerontology International.2025; 25(12): 1903. CrossRef
Genetic and Molecular Profiling of PLIN5 and LCN2 in Hepatocellular Carcinoma: Implications for Diagnosis and Prognosis Mahsa Sadat Reypour, Bita Moudi, Massoud Houshmand, Seyyedeh Behnaz Motahari International Journal of Infection.2025;[Epub] CrossRef
Dynamic changes and clinical value of lipocalin 2 in liver diseases caused by microbial infections Feng Chen, Shan-Shan Wu, Chao Chen, Cheng Zhou World Journal of Hepatology.2024; 16(2): 177. CrossRef
Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2 Eun-Ho Lee, Jae-Ho Lee, Do-Young Kim, Young-Seung Lee, Yunju Jo, Tam Dao, Kyung Eun Kim, Dae-Kyu Song, Ji Hae Seo, Young-Kyo Seo, Je Kyung Seong, Changjong Moon, Eugene Han, Mi Kyung Kim, Seungwan Ryu, Minsang Shin, Gu Seob Roh, Hye Ra Jung, Timothy F. Os Experimental & Molecular Medicine.2024; 56(4): 1001. CrossRef
The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction‐associated steatotic liver disease Ina Bergheim, José María Moreno‐Navarrete European Journal of Clinical Investigation.2024;[Epub] CrossRef
Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease Ahmed Mohamed ElGhandour, Nahla Mohamed Teama, Marwa Abdullah Kamal, Ehab Hassan Nashaat, Amani Mohamed Abdel Ghani, Ahmad Abbas Abdo Egyptian Liver Journal.2024;[Epub] CrossRef
Lipocalin-2 levels increase in plasma of non-alcoholic fatty liver disease patients with metabolic syndrome Hirdesh Chawla, Vivek Bhosale, Ravi Misra, Satyendra Kumar Sonkar, Neera Kohli, Naseem Jamal, Shobhit Raj Vimal, Banwari Dangi, Kavita Durgapal, Shail Singh, Mahendra Pal Singh Negi, Ashim Ghatak International Journal of Diabetes in Developing Countries.2023; 43(1): 105. CrossRef
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets Liu Yang, Yawen Hao, Joost Boeckmans, Robim M. Rodrigues, Yong He Pharmacology & Therapeutics.2023; 243: 108353. CrossRef
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef
LCN2 contributes to the improvement of nonalcoholic steatohepatitis by 8-Cetylberberine Huan He, Xue Chai, Juan Li, Changsheng Li, Xinran Wu, Xiaoli Ye, Hang Ma, Xuegang Li Life Sciences.2023; 321: 121595. CrossRef
Lipocalin-2 Secreted by the Liver Regulates Neuronal Cell Function Through AKT-Dependent Signaling in Hepatic Encephalopathy Mouse Model Danbi Jo, Yoon Seok Jung, Juhyun Song Clinical Nutrition Research.2023; 12(2): 154. CrossRef
From NAFLD to HCC: Advances in noninvasive diagnosis Qinchen Xu, Maoxiao Feng, Yidan Ren, Xiaoyan Liu, Huiru Gao, Zigan Li, Xin Su, Qin Wang, Yunshan Wang Biomedicine & Pharmacotherapy.2023; 165: 115028. CrossRef
The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery Jiaqi Chen, Shihui Lei, Yueye Huang, Xiaojuan Zha, Lei Gu, Donglei Zhou, Jun Li, Feng Liu, Nannan Li, Lei Du, Xiu Huang, Ziwei Lin, Le Bu, Shen Qu Lipids in Health and Disease.2022;[Epub] CrossRef
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis Ki Wung Chung, Ye Eun Cho, Seung-Jin Kim, Seonghwan Hwang Archives of Pharmacal Research.2022; 45(4): 229. CrossRef
Bioinformatics analysis reveals the changes of peroxisome proliferator-activated receptor (PPAR) pathway in the development of Marjolin ulcers Cheng Wang, Lin Cheng, Ying Zhang, Xiaozhuo Zhao, Huijun Zhang, Yuming Shen All Life.2022; 15(1): 960. CrossRef
A multi-omic landscape of steatosis-to-NASH progression Liping Xiang, Xiaoyan Li, Yunchen Luo, Bing Zhou, Yuejun Liu, Yao Li, Duojiao Wu, Lijing Jia, Pei-Wu Zhu, Ming-Hua Zheng, Hua Wang, Yan Lu Life Metabolism.2022; 1(3): 242. CrossRef
A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Marinela Krizanac, Paola Berenice Mass Sanchez, Ralf Weiskirchen, Anastasia Asimakopoulos International Journal of Molecular Sciences.2021; 22(6): 2865. CrossRef
Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis Seonghwan Hwang, Hwayoung Yun, Sungwon Moon, Ye Eun Cho, Bin Gao Frontiers in Endocrinology.2021;[Epub] CrossRef
First
Prev
